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ABSTRACT 
 
The NOD-like receptor protein NLRC5 inhibits TLR-induced NF-B and viral 
infection-mediated type I interferon signaling in vitro. In the first project, we generated 
NLRC5 knockout mice to characterize the regulatory function of NLRC5. NLRC5 
deficiency enhances Toll-like receptor-induced NF-B signaling and type I IFN- 
mediated antiviral immunity in mouse embryonic fibroblasts (MEFs). NLRC5 
deficiency also increases proinflammatory cytokine response and antiviral immunity in 
mouse immune cells. In addition, we confirmed that NLRC5 regulates the transcription 
of MHC class I gene. Our findings indicate that NLRC5 is a regulator with multiple 
functions by negatively regulating proinflammatory responses and positively regulating 
MHC class I gene expression. 
The inflammasome is a large protein complex that leads to apoptosis and 
proinflammatory responses. One of the well-studied inflammasome transduces the 
activation signal through NLRP3. NLRP3 inflammasome is known to be activated 
through ASC oligomerization induced by varieties of stimulations; however, the 
mechanism remains unknown. Some of the DDX family proteins have been reported to 
sense DNA or RNA to activate type I IFN signaling pathway. By screening DDX family 
proteins in 293T cells reconstituted with the inflammasome system, we found that 
DDX46 enhanced NLRP3 inflammasome activity. Knockdown of DDX46 in THP-1 
cells reduces inflammasome activity and IL-1 release after crystalline stimulations. 
DDX46 is cleaved by activated caspase-3 after silica stimulation in mouse macrophages. 
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Furthermore, cleaved DDX46 interacts with the NLRP-ASC complex following silica 
stimulation. The positive regulatory role of cleaved DDX46 in silica-mediated NLRP3 
inflammasome activation was confirmed in the 293T cell system by its strong ability to 
interact with ASC. Together, our findings indicate that cleaved DDX46 acts as a bridge 
to promote the interaction between NLRP3 and ASC after crystalline stimulation. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Overview of Immunology 
 
The utmost important task of the immune system is to protect self and respond to 
nonself. T and B lymphocytes use VDJ recombination to generate precursor cells 
carrying different T cell receptors (TCR) or B cell receptors (BCR) respectively. Each 
clone of T cell or B cell is undergoing clonal deletion if the progenitor cell is able to 
detect self-antigens presented in the thymus or bone marrow. This process is called 
negative selection (Palmer, 2003).  Although other mechanisms such as anergy 
(Hammerling et al., 1991) and receptor editing(McGargill et al., 2000; Wang et al., 
1998) exist in the periphery to induce tolerance to self, the central tolerance is 
considered to play a major role to select or train T cell and B cell clones to react only to 
nonself- antigens. The discovery of the theory of negative selection won the Nobel Prize 
for Burnet and Medawar in 1960 and ever since the self-nonself discrimination model 
has played a dominant role for several decades.  
But the major problem of self-nonself model is that not only in vitro, but also in 
vivo studies showed that a robust immune responds for T cells need co-stimulation 
signals. The recognition of nonself-antigen alone is not sufficient to induce adaptive 
immune response. For example, injection of ovalbumin antigen subcutaneously, 
intravenously, or intraperitoneally will not elicit an immune response against it unless a 
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second agent is applied which is called adjuvant. One of the most commonly used 
adjuvant is complete Fraud’s adjuvant (CFA) which contains inactivated and dried 
mycobacteria in mineral oil. In 1989, Charles Janeway suggested an ingenious model 
suggesting the capability of antigen presenting cells (APCs), such as macrophages, 
dendritic cells to recognize a bunch of evolutionarily conserved pathogen molecules 
which are referred as pathogen-associated molecular patterns (PAMPs) from microbial 
pathogens such as bacteria and viruses. Upon recognition of these PAMPs by a set of 
receptors encoded in germline by APCs, they are able to up-regulate co-stimulatory 
molecules and co-stimulatory cytokines to facilitate T cell activation. The discovery of 
Toll-like receptors, which represents one crucial member of pattern recognition receptors 
(PRRs) is rewarded for the Nobel Prize in 2011 for Physiology or Medicine. According 
to the infectious-nonself model the T cells will only respond to non-self only if there is 
innate immune system providing appropriate stimulatory signals upon recognition of 
PAMPs. Thus, the choice of responding or not responding to antigens is mainly depend 
on the innate immune receptors when they encounter appropriate stimulation such as 
LPS. 
 
Innate Immunity 
 
Innate immune system acts as a sentinel of the mammalian body; it senses or 
recognizes microbial pathogens the instant they invade the body, and defends the 
pathogens through phagocytosis or pro-inflammatory responses. A wide variety of cells 
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contribute to the cellular composition of the innate immune system. It involves almost 
all the white blood cells except for T and B cells. It also involves epithelial cells such as 
skin, gut and lung cells that line our internal area of the body. The innate immune system 
can directly prevent bacterial invasion through cellular engulfment of pathogens and 
digesting bacteria within cells. Neutrophils and macrophages are two of the well-known 
immune cell types that have the ability to clear infections through this mechanism. In 
tissue epithelial cells, they can secret antimicrobial peptides to combat microbes. Unlike 
adaptive immune system, innate immune response is non-specific to the pathogen, and 
does not maintain the memory for defending the infection. In addition, compared to the 
later emergence of adaptive immunity, the innate immune system exists in not only 
vertebrates, but also in invertebrates and plants which are evolutionary more ancient 
species. Considering the prosperous of species of plants and invertebrates, the innate 
immune system’s success is out of doubt. The appearance of adaptive immunity indeed 
added a lot of specificity of immune responses due to the TCR and BCR recombination 
and selection in the central immune organs. Yet, adaptive immunity also brought up 
problems such as autoimmune diseases and allograft rejection. Accordingly, the adaptive 
immunity is still tightly regulated by co-stimulatory molecules. Inflammatory cytokines 
are also acting as a co-stimulatory factor to activate the adaptive immunity. The 
upregulation of co-stimulatory molecules and proinflammatory cytokines requires the 
NF-B signaling which is a key player in innate immunity. Finding regulators of the NF-
B signaling pathway is very important to understand and intervene such pivotal 
signaling.  
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Pattern Recognition Receptors (PRRs) 
 
PRRs are receptors which can detect or sense conserved molecule from microbial 
called pathogen associated molecular patterns (PAMPs) and they are either in the 
cytoplasm or on the cell surface. Once the host is challenged by a potential infection or 
factors regarding as “danger” signals which are present in response to pathogenic 
infection, cell stress, or sterile inflammation, the PRRs  sensing the infectious molecules 
or danger signals, could  induce a cascade of signaling pathways that involves assembly 
of adaptor molecules, activation of  kinases and transcriptional factors, and ultimately 
lead to the upregulated gene expression of important molecules, such as cytokines, 
adhesion molecules and co-stimulatory molecules. These effector molecules result in the 
initiation of immune response and mount an effective adaptive immune response. 
Several classes of PRRs are characterized such as TLRs (Toll-like receptors) which is 
the earliest one identified RLRs (RIG-I-like receptors) that mainly detect viral infection 
and NLRs (NOD-like receptors) which play multiple functions in immune system. 
 
Toll-like Receptors (TLRs) and NF-B Activation 
 
Ten members of TLRs have been characterized in human. They are distinguished 
from each other by their ligand specificities.  TLRs can bind to a variety of 
evolutionarily conserved pathogenic molecules such as Lipopolysaccharide, 
peptidoglycan, flagellin, CpG or unmethylated cytosine-guanine dinucleotide or 
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sequences from the genome of bacteria or virus, zymosan from fungi, dsRNA and 
ssRNA. Some TLRs needs additional PAMP-binding molecule to recognize the ligand, 
for example, LPS recognition by TLR4 is mediated by an accessory molecule named 
MD2. TLRs can act as both PAMP and DAMP sensors. For instance, besides LPS, 
TLR4 can also recognize structurally and biochemically diverse ligands such as the 
fusion protein from virus such as respiratory syncytial virus and some heat shock 
molecules. Upon activation by ligand binding, TLRs trigger a common signaling 
pathway that activates NF-B signaling pathway. Take TLR4 as an example, once the 
ligand LPS is bound to the receptor, the adaptor protein Myd88 is recruited (Medzhitov 
et al., 1998; Muzio et al., 1998). The C-terminal of Myd88 is responsible for interaction 
with the TLR complex and the N-terminal is responsible for recruiting downstream 
adaptor protein IRAK4 (Wesche et al., 1997). IRAK4 is a serine threonine kinase which 
can autophosphorylate itself and recruit TRAF6. TRAF6 has a RING finger domain 
which acts as an ubiquitin E3 ligase and promotes the assembly the K63-linked ubiquitin 
chains. These ubiquitination chains provide interaction sites where TAK1/TAB1/TAB2 
complexes are formed (Xia et al., 2009). The complex phosphorylates IKK and 
activates IKK complex phosphorylates, resulting in the degradation of IB which is the 
inhibitor of nucleic transportation of NF-B transcription factor. Thereby, P65 and RelA 
is released and transferred to the nucleus and activate the downstream target gene 
expression (Muzio et al., 1998). NF-B activation plays a central role in bridging the 
innate immune responses with effective adaptive immune responses because it mediates 
and co-operates the expression of multiple genes that are essential to mount effective 
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immune response. The NF-B regulated genes include genes transcript pro-
inflammatory cytokines such as pro-IL-1, IL-6 and TNF-; genes encoding 
chemokines such as IL-8 and RANTES; genes encoding cell adhesion molecules; and 
those transcript co-stimulatory molecules such as B6 family members CD80 and CD86. 
These effector molecules together promote the phagocytosis of microbial pathogens, 
enhance killing of target bacteria utilizing complement or NK cells, and promote antigen 
presentation and recognition. Moreover, the NF-B signaling pathways are often 
associated with cellular growth and apoptosis inhibition, thus is promotes the expansion 
and persistence of cellular immunity. The activation of NF-B as described is obviously 
a complex multistep signaling cascade which can be targeted at different levels.  
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CHAPTER II 
FUNCTIONAL CHARACTERIZATION OF NLRC5 IN THE 
REGULATION OF INNATE IMMUNE RESPONSES
*
 
 
Introduction 
 
Regulation of NF-B signaling 
Because uncontrolled activation of NF-B signaling will cause secretion of large 
amounts of inflammatory cytokines which will cause uncontrolled activation of T cells 
leading to autoimmunity or overwhelming cytokine storm can cause septic shock and 
death of the organism. In this regard, regulating, especially negative regulation of NF-B 
signaling pathway is truly critical in balancing effective immune response versus 
uncontrolled inflammation and tissue damage. Generally speaking, the degradation of 
adaptor molecules in the signaling pathway is a basic mechanism of terminating an 
activation signal. In mammalian cells, the degradation of a particular protein is usually 
mediated by proteasome which recognizes K48 poly-ubiquitination modification. A 
typical example of degradation of TLRs is Triad3A which is a protein containing RING 
finger domain. Traid3A was initially discovered by yeast-two-hybrid of TLR9 TIR 
                                                 
*
 Part of the data reported in this chapter is reprinted with permission from “Enhanced TLR-induced NF-
B signaling and type I interferon responses in NLRC5 deficient mice” by Tong, Y., Cui, J., Li, Q., Zou, 
J., Wang, Y., Wang, R. (2012). Cell Research 22, 822-835.  Copyright [2012] by Cell Research. 
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domain and was later proved to be interacting with multiple TLRs such as TLR3, TLR4. 
Overexpression of Triad3A caused  the degradation of interacting TLRs (Chuang and 
Ulevitch, 2004). 
Of course, K48-polyubiquitination is not the only way to negatively regulate NF-
B signaling pathway, there are other mechanisms involving ubiquitination. It is notable 
that K63 polyubiquitination is very critical in NF-B activation, thus, de-ubiquitinate 
K63 polyubiquitin chain can be efficient ways to shut off the signaling. The well-known 
example of this class is the discovery of deubiquitinase A20. A20 is a Zinc-finger 
protein, which is induced by TNF. A20 can also act as a negative feedback loop though 
its regulatory function, to regulate TNF induced NF-B activation. The target of A20 is 
RIP1, which is a critical adaptor protein in TNF induced signaling pathway. 
Deubiquitinate K63 poly-ubiquitin chain of RIP1 cause its loss of function to conduct 
activation signals downstream (Sun, 2008). Indeed, A20 deficient mice have profound 
systematic inflammation. But crossing A20 KO mice with TNFR KO mice cannot rescue 
all the phenotype indicating that A20 has targets other than RIP1. Later, it was found 
that N-terminal OUT-like domain of A20 can remove K63 poly-ubiquitin chain on 
TRAF6 and shutdown TLR induced NF-B activation as well (Boone et al., 2004). 
Another deubiquitinating enzyme called deubiquitinating enzyme A (DUBA) is 
also an important negative regulator of deubiquitinase. DUBA and A20 belong to the 
same family consisted of 14 members. The signature motif of the family is OUT domain. 
DUBA targets TRAF3 and prevent the autoubiquitination of TRAF3 (Kayagaki et al., 
2007). 
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Another family of deubiquitinase is USP (ubiquitin-specific protease) family. 
One important member of this family is CYLD. CYLD has multiple target proteins such 
as TRAFs, NEMO, Bcl3, TAK1 and RIP1. Knockdown of CYLD could increase both 
NF-B and p38 MAPK activity (Yoshida et al., 2005). Another common mechanism of 
negative regulation is competitive binding of adaptor proteins. As previously stated, the 
TLR signaling pathway is conducted by proteins using similar domain for interaction, 
for example, TIR domain. Adaptor proteins: Myd88, Mal, TRIF, TRAM all have the 
TIR domain to mediate interaction and assembly of complexes. SARM is a protein 
which also has TIR domain but does not mediate positive signaling. Thus by competing 
with signaling molecules, SARM is using its TIR domain to sequester NF-B activation. 
Knockdown of SARM could significantly enhance LPS induced cytokine production 
(Carty et al., 2006). At the receptor level, RP105 (Radioprotective 105) is highly 
homologous to TLR4. Like TLRs, RP105 is rich of extracellular LRR repeats but no TIR 
structures. Thus, RP105 could compete with TLR4 to bind to MD2 and form 
TLR4/MD2 complex, thereby negatively regulating TLR4 signaling (Divanovic et al., 
2005). 
Another important mechanism to generate competitive binding proteins is by 
alternative splicing. Until now, many adaptive proteins in the TLR signaling pathways 
have been discovered to have alternative splice forms to compete with full length 
adaptive proteins. One important example is the discovery of Myd88s. Myd88 is a 
crucial adaptive protein in all of the TLR mediated signaling except for TLR3. It mainly 
has three structural domains: 1) N-terminal DD domain, 2) middle domain and 3) TIR 
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domain. Myd88s, one isoform of Myd88, does not contain the middle domain and inhibit 
the activation of TLR signaling pathway. Evidences showed that exogenous expressed 
Myd88s inhibits TLR-induced NF-B signaling, because Myd88 and Myd88s could 
form a heterodimer and recruit IRAK1 but fails to phosphorylate IRAK1, thus shutting 
down the signaling (Burns et al., 2003; Janssens et al., 2002).  
 
RIG-I like receptors and type I IFN pathway 
TLRs are mainly expressed on the cellular membrane system including cell 
surface membrane or membrane system of endosome or lysosome, they are not capable 
to recognize intracellular cytosolic pathogens that are not involving endocytosis. In 
addition, in TLR3/TLR9 or even TRIF/Myd88 double knockout mice, the mice are still 
able to induce type I IFNs upon viral infections. This strongly indicates that other TLR 
independent recognition of intracellular molecular patterns is needed to the signaling 
activation. Generally speaking, virus infection can trigger IRF3 or IRF7 activation  to 
produce type I IFNs. Type I IFNs includes IFN- and several subtypes of IFN-, which 
are very crucial for host cells to combat the virus infection and restrain the virus 
reproduction. Until now, at least two types of PRRs are regarded to recognize viral 
PAMPs. One is toll-like receptor as described above; the other RIG-I like receptors 
(RLRs). This family of receptors so far has been identified to include RIG-I, dicer 2 and 
MDA5 (melanoma differentiation-associated gene 5). They are responsible to recognize 
virus-differentiated PAMPs. Kato and his colleagues demonstrated that RIG-I KO MEFs 
are defective to respond to some kinds of viruses such as type A influenza virus, JEV 
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(Kato et al., 2006), whereas MDA5 KO MEFs responds normally to these viruses. In 
contrast, MDA5 KO MEFs cannot respond to small RNA viruses such as EMCV, 
whereas the antiviral response in RIG-I KO MEFs is normal when infected by these 
viruses. Structural analysis of RIG-I revealed that the N terminus CARD domain is 
important for activation. The C terminus region masks the N terminus CARD domain 
when the protein is inactivated. Upon activation, the CARD domain of RIG-I is exposed 
and easily to form dimers and recruit MAVS (mitochondrial antiviral signaling), to 
activate type I IFN secretion pathway sequentially through signaling molecules TBK1, 
IKKi, IRF3 and IRF7. Recently, stimulator of IFN genes (STING), mainly function as an 
adaptor protein was described by a different group. Although STING is proved to be 
present on the mitochondrial membrane, it can also interact with RIG-I and MAVS, 
providing critical links to the cross talk of signals from both the mitochondria and ER. In 
one study, the HSV-infected mouse macrophages generated a lot of mitochondrial ROS 
and in response to the alternation of ROS concentration; calcium release from the ER 
was further activated. This response then lead to the activation of P38, JNK or NF-B 
activation through TAK1 mediated signaling (Mogensen et al., 2003). In the RLR 
signaling pathway, MAVS is proved to be the divergent point of IRF transcriptional 
factors and NF-B activation. TNF receptor-associated death domain (TRADD) is 
recruited to mitochondrial protein MAVS and form a complex with MAVS. TRADD 
then recruits the TRAF3 and TANK to activate the TBK1/IKKi complex. And then the 
activated complex phosphorylates IRF3/IRF7, leading to the transcripti  on of IFN-
(Guo and Cheng, 2007; Kato et al., 2005; Michallet et al., 2008; Saha et al., 2006; 
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Yoneyama et al., 2004). In the meantime, by utilizing the Fas associated death domain, 
the MAVS/TRADD complex also activates the signal to NF-B based on the interaction 
between this complex and RIP1 and caspase8. These complexes activate the IKK 
complex and lead to NF-B activation.  
 
Virus evasion strategies and downregulation of type I IFN pathway 
Viruses, during the evolution and selection by environment, have developed 
advanced mechanism to interfere the antiviral responses, particularly the production of 
type I IFN. Generally, viruses are able to block functional molecules which are 
participating in the activation of NF-B or IRF pathways to inhibit the production of 
IFNs. One of the immediate early proteins generated by viruses such as HSV-1, for 
instance, infected-cell protein o (ICPo) negatively regulates the activation of IRF3 and 
IRF7 (Lin et al., 2004). Similarly, NS1/2 of RSV inhibits IRF3 phosphorylation 
mediated by TBK1 (Spann et al., 2005). Likewise, measles virus inhibits 
phosphorylation of IRF7 (Schlender et al., 2005). The most extensively studied molecule 
is NS3/4 serine protease bio-synthetically produced and released by hepatitis C virus. It 
can cleave adaptor molecule TRIF to inhibit TLR3 responses and also cleave MAVS to 
prevent RLR-mediated signaling pathways and the signaling activated production of 
antiviral proteins called type I IFNs (Li et al., 2005; Meylan et al., 2005). Some 
paramyxoviruses can inhibit the MDA5 recognition by the viral V protein (Andrejeva et 
al., 2004). VP35 of Ebola virus and NS1 of influenza A virus inhibits the interaction 
between RIG-I and MAVS after the viral RNA is recognized by RIG-I. (Cardenas et al., 
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2006; Mibayashi et al., 2007). Recently, another mechanism of avoiding RIG-I 
recognition has been described. Some viruses such as Crimean-Congo HFV, Hantaan 
virus and Borna disease virus can remove of 5’-triphospate RNA from their genome 
RNA post-transcriptionally to prevent RIG-I binding and activation (Habjan et al., 
2008). Finally, IFNs once have been transcribed, viruses have also developed post-
transcriptional strategies to prevent the cytokine from being processed. For example, 
VSV M protein can inhibit the export of the transcript of IFN from the nucleus to the 
sites for translation in the cytoplasm (Her et al., 1997). In addition, HSV-1 can 
destabilize proinflammatory cytokine mRNAs by ICP4 and ICP27, which are viral 
immediate early proteins (Mogensen et al., 2004). 
Although the innate immune response to virus stimuli is essential, over reaction 
to such stimuli can do harm to the host as well. Thus, strict regulations of type I IFN 
pathways are needed. There are a lot of negative regulators have been found to 
participate in down-regulating the pathway such as A20, Pin1, SIKE, RNF5, DUBA and 
DAK (Diao et al., 2007; Huang et al., 2005; Kayagaki et al., 2007; Lin et al., 2006; 
Saitoh et al., 2006; Zhong et al., 2009). Different molecules utilize different target and 
strategy to act as negative regulators of the type I IFN pathway. Here we found NLRC5, 
which belongs to a Nod-like receptor superfamily, can regulate type I IFN pathway at 
the receptor level and by generating KO mice, we are going to validate its role in vivo by 
infecting the mice with VSV or influenza viruses to analyze the physiological function 
of NLRC5 in the regulation of type I IFN pathways. 
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Nod-like receptors (NLRs) 
The general paradigm of extracellular bacteria PAMP recognition about a decade 
ago is mainly through the TLRs as introduced above. But in the past 10 years, a group of 
intracellular receptors: NOD-like receptors are found to be one of the PRR families that 
can recognize PAMPs. NLRs share a typical tripartite structure including a conserved 
domain capable to bind to nucleotide, NACHT. They also contain a C-terminal formed 
by a number of leucine-rich repeats (LRRs), which is estimated to be able to sense 
PAMPs, and is named LRR domain. In addition, some NLRs have a pyrin domain 
(PYD) in the N-terminus, while some may contain a caspase-activation and recruitment 
domain (CARD). Until today, there are about 23 characterized NLR family members 
playing a role in cellular processes such as pathogen recognition, apoptosis, gut 
development and inflammasome activation(Kufer and Sansonetti, 2011). Three NLR are 
identified: 1) the NLRC family which has CARD domains in its N-terminal, 2) the NAIP 
family which has BIR domain in the N terminus of the protein, and 3) NLRP family 
which has PYD domain as a specific N terminal domain. NLRP family contains 14 
family members. Two of the NLRC proteins, NOD1 and NOD2 were reported to be 
capable to recognize of bacteria (Strober et al., 2006). Among the NLRP family 
members, NLRP3 is the most extensively studied member which plays an important role 
in activation of inflammasome  (Tschopp and Schroder, 2010). Functions of other NLRP 
members were also studied recently. For example, NLRP1 can form inflammasome after 
sensing of Bacillus anthracis toxin(Levinsohn et al., 2012). NLRP4 is another NLRC 
protein that has been reported to be a negative regulator of virus-induced type I 
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interferon signaling via degradation of TBK1(Cui et al., 2012). NLRP6 negatively 
regulates TLR signaling pathway and promote the secretion of mature IL-18 through 
inflammasome activation to promote tissue repair in the intestine (Anand et al., 2012; 
Elinav et al., 2011). NLRP7 is also important for inflammasome activation when the 
lipopeptides from pathogens are sensed by the receptors (Khare et al., 2012). NLRP10 is 
reported to induce dendritic cell activation and initiate adaptive immunity through 
cytokine induced regulations (Eisenbarth et al., 2012); Pathogenic molecules from the 
Yersinia pestis can be recognized by innate immune system and activate NLRP12 
inflammasome (Vladimer et al., 2012) as well as suppress colon inflammation and 
tumorigenesis by regulating NF-B signaling pathway (Allen et al., 2012; Zaki et al., 
2011). Thus the functions of NOD-like receptors vary from modulating NF-B 
signaling, recognizing pathogens, and regulating adaptive immunity, to activating 
tumorigenesis and inflammasome. 
 
NLRC5 
Human NLRC5 consists of 1866 amino acids and mouse NLRC5 consists of 
1915 amino acids. They are highly conserved, 64% of the amino acids are identical 
between human and mouse NLRC5. It is the largest protein among the five NLRCs in 
the family. The C-terminal LRR domain is extremely long, containing 27 LRRs. The 
homologous alignment shows that NLRC5 is mostly close to CIITA which can be 
transported into nucleus directed by the nuclear localization signals (NLSs) (Benko et al., 
2010; Meissner et al., 2010) and regulating MHCII gene transactivation (Camacho-
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Carvajal et al., 2004). In addition, the N terminus of NLRC5 protein is also found to 
have NLS, suggesting a role of NLRC5 in the nucleus. In fact, overexpression of 
NLRC5 is truly found to be mainly localized in the nucleus whereas endogenous NLRC5 
is found to be in both nucleus and cytoplasm. Inhibition of NLRC5 to be transported into 
cytoplasm can be achieved by LepB, which is an inhibitor of protein nucleus export 
(Neerincx et al., 2010; Staehli et al., 2012). 
Expression of NLRC5 is widely detected in cells and tissues, and the expression 
level of the protein in the spleen, lymph node, and other organs important for immune 
response is found to be especially which suggests its function in immunity (Cui et al., 
2010). Moreover, NLRC5 expression is inducible in response to stimuli such as type I 
IFN, type II IFN and LPS (Cui et al., 2010; Staehli et al., 2012; Yao et al., 2012). 
Interestingly, the induction of NLRC5 in response to LPS does not signal through 
adaptor protein Myd88 but through TRIF suggesting that LPS-induced expression of 
NLRC5 may due to the type I interferon release when TLR is activated (Staehli et al., 
2012). People tried to analyze the interactive ability of promoter region of NLRC5 with 
transcription factors by CHIP-Sequencing and found that both STAT1 and NF-B have 
putative binding site with NLRC5 promoter (Kuenzel et al., 2010) , thus to determine 
exactly how NLRC5 is regulated is needed by utilizing genetic models such as STAT1 
KO mice.  
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Function of NLRC5 in innate immunity 
Previous studies have reported that NLRC5 plays a negative regulatory role in 
the signaling pathway of NF-B activation and anti-viral response (Benko et al., 2010; 
Cui et al., 2010; Neerincx et al., 2010). In the NF-B signaling pathway, NLRC5 
interacts with IKKs and mediates K48 ubiquitination and degradation to shut down the 
NF-B signaling pathway, whereas in type I interferon producing pathway, NLRC5 is 
suggested to prevent activation of type I IFN signaling by interacts with RIG-I like 
receptors (Cui et al., 2010). Nevertheless, whether NLRC5 is playing such roles in vivo 
is not clear. Here, by constructing a knockout mouse by site-specific targeting exon 8, 
we are able to characterize the role of NLRC5 in vivo in primary mice immune cells 
such as MEFs, peritoneal macrophages, BMDCs, BMMs and at the whole mouse level. 
 
Materials and Methods 
 
Generation of NLRC5-deficient mice  
In the cDNA of mouse NLRC5, the eighth exon encodes partial region of the 
gene expressing functional domain of the protein, called LRR1domain. We constructed 
the targeting vector and removed exon 8 through homologous recombination at the 
region where the target gene and the constructed vector share identical sequence. And 
the insert of constructed sequence with a Neo cassette resulted in incomplete 
transcription of NLRC5. The linear fragments of targeting vector were transfected into 
embryonic stem (ES) cells by electroporation. Then we did PCR and Southern blot to 
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verify the homologous recombinant stem cells. The ES cells were selected with 
neomycine to get the cells undergo recombination. Simultaneously, the cells with non-
specific recombination were killed by the treatment of gancyclvir. The ES cells, after 
selection, were put back into blastocysts. And then they were put into several embryos of 
white-fur mice. If a mouse is with the genes after recombination in the skin cells, it 
would appear as chimeric mouse. Using the chimeric mice for breeding, we were 
expecting to get some gray-fur mice, which is heterozygous for NLRC5 knockout allele. 
Grey mice were used to set up breeding pairs to give birth to homozygous NLRC5 
knockout mice.  
 
Cell culture and stimulation   
Mice were sacrificed around day 15 of pregnancy to generate Mouse embryonic 
fibroblasts (MEFs). The embryo tissues were cut into small pieces, and then we treated 
the cells with trypsin to separate the link between MEF cells by degrading the collagen 
between cells. The single cell suspension were then washed to remove the reagents and 
cultured in MEF medium.  
Peritoneal macrophage extraction: each mouse was injected with 3 mL 
thioglycollate medium through intra-peritoneal injection 4 days before cell harvesting 
day. On the cells extraction day, mice were sacrificed by CO2 and cervical dislocation, 
then the fur covering the abdomen were dispelled from the peritoneal. Inject 10 mL of 
3%FBS/PBS into the peritoneal cavity, massage the abdomen for 20 times by gently 
shaking, and collect the lavage with cells by syringe. Cells were allowed for attaching in 
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the petri dish with culture medium for 3 h, and the floating cells after that were removed 
by washing with PBS for three times. The attached cells were collected and seeded for 
experiment. 
Generation of bone marrow-derived macrophages (BMM) and dendritic cells 
(BMDC): tibia and femur were removed from the sacrificed mice, and the flesh was 
removed using disinfected scissors. Cut both ends of the bones and flush out the bone 
marrow using syringe with RPMI medium. Cells were treated with Red blood cell lysis 
buffer and washed with medium for twice, and then the resuspended cells were counted 
for seeding. Cells were seeded with RPMI1640 containing 10% FBS, 55 μM β-
mercaptoethanol, 1% penicillin-streptomycin, and appropriate amount of  L929 
conditioned media for 4 days for the bone marrow progenitor cells to differentiate into 
BMMs. Or the progenitor cells were cultured with RPMI 1640 supplemented with 10 
ng/ml mouse GM-CSF, and allow the cells to differentiate in to BMDCs for at least 7 
days. In the cell stimulation experiments, mouse macrophages and dendritic cells were 
treated with TLR4 specific ligand LPS (100 ng/ml), TLR2 specific ligand Pam3CSK4 (1 
μg/ml), TLR9 specific ligand CpG (2 μg/ml), TLR7 specific ligand CL-097 (1 μg/ml), 
TLR3 specific ligand polyinosinic-polycytidylic acid (poly(I:C)) (20 μg/ml) for 
indicated time points. LPS is produced by Sigma-Aldrich. Other TLR agonists such as 
CpG, poly (I:C) are the products of  Invivogen.  
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Flow cytometry  
For the analysis, the cells are stained with Fluorescence conjugated antibodies 
All these antibodies were the products of BD Pharmingen. Before staining, cells were 
purified by positive or negative selection so that the cells are not damaged during 
analysis on the flow cytometry and also permit a lower background. Purified cells were 
washed with staining buffer. We used 1%FBS/PBS with 0.1% Azide to be isotonic and 
buffer to neutrality, meanwhile cushion the centrifugation pressure, block non-specific 
binding, prevent and block Fc receptor binding.  Adjust density of cell suspension to 
about 5 million cells/ml. The number of viable cells is expected to be no less than 90% 
of the total cells, measured by trypan blue exclusion. Cells were centrifuged at 400 rpm 
for 5 minutes. The medium were carefully aspirated, and the cells were stained with 
100ul of first antibody diluted in the staining buffer. Incubate the staining samples for 30 
min at 4
o
C in dark. Wash the cells three times after staining. After wash, the stained cells 
were flicked and resuspended with100ul of secondary antibody if necessary. After that, 
we resuspended the stained cells with 100ul of staining buffer and transferred the 
mixture to FACS tubes containing 400ul staining buffer for analysis. Cells need to be 
placed on ice when handling.  
 
Cytokine release analysis 
In our study, to treat the cells, MEF cells or macrophages were incubated in the 
medium with indicated stimuli. The cell culture supernatants at different time point were 
collected and analyzed for cytokine release with commercial ELISA kits which detect 
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indicated cytokines we studied in this project. These kits were purchased from 
eBiosceince and IFN- detecting set is from PBL Biomedical Laboratories. Analysis 
was carried out according to manufacturer’s instructions. To challenge the mice in vivo 
such as LPS injection, we used a dose of 25 mg/kg for intraperitoneal injection, and then 
we collected sera of the mouse at indicated time points after injection. The serum was 
analyzed for the release of IL-6 and TNF-. To do the in vivo challenge of virus, mice 
were intravenously injected with VSV-eGFP. And the type I interferon release in the 
sera were analyzed using ELISA. 
 
ELISA 
Sample preparation: Cell culture supernatants were collected into 1.5 mL tubes at 
different time points as indicated. To remove the cell debris or any other residue of the 
reagent of treatment in order to avoid any factors that affect the ELISA efficiency, 
centrifuge the tubes at 12,000 g for 5 min, the supernatant after centrifugation were 
collected in a new tube. For stocking, freeze the samples in -80
o
C so that the bioactive 
molecules are not degraded. ELISA plate preparation: Dilute capture antibody in PBS as 
instructed, use 100 ul of the diluent for each well, and coat the plate for first antibody 
binding in 4 degree overnight. On the second day, wash the plate with 0.5% Tween/PBS 
for three times, and incubate each well with 200 ul of 1%BSA/PBS for 2 hours to block 
the non-specific binding site on the plate. Prepare sample diluents and standard gradient 
samples with sample diluents buffer, and add 100 ul sample diluents to each well. The 
loaded plate are then incubated in dark for 2 hours, followed by a 3-time wash. Incubate 
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each well with detection antibody diluents for 2 hours, followed by 0.5 hour incubation 
of HRP. Wash the plate for 5-6 times with the wash buffer, and add 100 ul of biotin 
substrate to initiate the reaction. Then we use 50 ul stop buffer to terminate the substrate 
reaction. The absorbance was measured using plate reader. The raw data were analyzed 
using Excel to generate the standard curve and to calculate the concentration of 
cytokines in the supernatant before dilution. 
 
Total RNA extraction 
Experimentally treated cells were treated with Trizol (invitrogen), mix the lysate 
thoroughly to homogenize the lysate. 100 ul of chloroform were added to each 500 ul of 
Trizol lysate. Vortex the mixture to completely mix the substances. Sit the tube at room 
temperature for 5 min, and then centrifuge the samples at 12,000 xg for 15 min. 
Carefully collect the supernatant after centrifuging, and add equal volume of 
isopropanol, mix thoroughly and sit in room temperature for 7 min and then centrifuge 
the samples at 12,000 xg for 10 min.  The RNA pellet was washed for 2 times with 75% 
ethanol to remove the organic diluents. Then, dry the pellet on dry tissue by inverting the 
tube for 15 min. Dissolve the RNA pellet using molecular grade water then the pellet 
appears to be transparent. Pipet the diluents up and down to dissolve the RNA 
completely, incubate the tube in 65 centigrade to accelerate dissolution if necessary. We 
measured RNA concentration after complete dissolution.  
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Western blot 
Before collecting the treated cells, we washed the wells with PBS and then add 
low salt lysis buffer or RIPA buffer to lyse the cells and release the protein. For 
attaching cells, we used cell scraper or trypsin to release the cells from the bottom, and 
then collect the cells with Eppendorf tubes and add lysis buffer. The samples were 
inverted in the 4 degree shaker for 20 minutes for the protein released from the 
cytoplasm and then spun down. Then we stock the supernatants for analysis. The 
resulting lysate was first measured for protein concentration by BCA protein 
quantification protocol and then frozen for later use.  Upon western blot analysis, the 
protein lysates were diluted to the equal total amount of protein with the lysis buffer and 
then mixed with SDS-loading buffer. We then boiled the mixture of lysate and loading 
buffer for 5 minutes at 100°C, and then loaded the denatured protein samples onto SDS-
PAGE gel to run western using 80 V for to stack the protein in the upper layer gel, and 
later at 120 V to separate the protein in the lower layer gel. After this step, the gel was 
transferred on to a nitrocellulose membrane using wet transfer system at 100 V for 90 
min. Then the membrane was blocked and blotted with indicated antibody using gel 
imaging system. 
 
Serum collection 
Blood collection from mouse tail: Warm the mouse and put it into a restraining 
tube. Rub the tail from bottom to tip, so that the blood flow does not increase. Using a 
straight edge razor quickly remove about 1 cm of the tail. We used a capillary tube to 
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suck the blood and transferred the blood to tubes. Apply pressure to stop the bleeding 
after collecting the blood. In our case, several samples are needed for different time 
point after challenge within several hours; we removed the clot to open the existed 
wound to collect blood samples. Allow the blood to clot for 30 min at ambient 
temperature (19-24°C) , and then Centrifuge the sample for 10 min at 2200 G. Separate 
the serum and plasma by removing the transparent supernatant after centrifuging. Pipette 
aliquots of samples for several separate uses and store samples at -80 °C, make sure to 
avoid freeze-thaw cycles to keep the concentration of bioactive cytokine and chemokines 
at the original level. 
 
Virus titration 
Seed 2x10
4
 cells in each well of 96-well plate. One the second day, dilute the 
virus concentrate with medium by 10 time for 10 times. Remove the medium in the well, 
and add 120 ul of diluted virus into each well. Use duplicate for each dilution. Exam the 
infected cells 24 hours after infection under fluorescence microscopy to detect the 
infection of eGFP tagged virus infection. Then, the virus titer was determined. 
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Results 
 
NLRC5 induction is dependent on Stat1signaling pathway 
NLRC5 expression is reported to be induced by cytokines such as IFN- and 
IFN-, as well as TLR ligands. However, the mechanism how NLRC5 is induced has not 
been studies yet (Benko et al., 2010; Cui et al., 2010; Kuenzel et al., 2010; Neerincx et 
al., 2010). Previous study of our group showed that LPS can induce NLRC5 expression 
in mice macrophages, but we are not clear whether LPS induce NLRC5 directly through 
TLR-induced NF-B signaling pathway or through other mechanisms. To test whether 
NLRC5 is induced by NF-B, we examined NLRC5 mRNA transcription in response to 
LPS or IFN-stimulation in mouse peritoneal macrophages of MyD88-/- and IRAK4-/-. 
LPS induced TLR4 signaling pathway is dependent on Myd88 and Irak4 to activate NF-
B signaling. Thus, MyD88-/- an Irak4-/- cells will not be able to activate LPS-induced 
NF-B signaling. When we treated the MyD88-/- or IRAK4-/- macrophages with LPS, we 
found that the induced expression of NLRC5 mRNA was completely shut down in these 
cells (Figure 1A), indicating that LPS induced NLRC5 relies on Myd88 and Irak4 
dependent NF-B pathway.  However, NLRC5 induction in response to IFN- treatment 
in absent of Myd88 or Irak4 was comparable to the induction pattern in wild-type (WT) 
cells, suggesting that IFN- induce NLRC5 expression is independent of Myd88 and 
Irak4 induced NF-B signaling.  
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Figure 1. LPS induced NLRC5 in a Stat1-dependent manner. (A) Peritoneal 
macrophages isolated from WT, Myd88
-/-
 or Irak4
-/-
 mice were treated with LPS (100 
ng/mL) or IFN- (1000 U/mL). Total RNA was collected at indicated time points. The 
transcription level of NLRC5 mRNA was measured by real-time. (B) Peritoneal 
macrophages from WT or Stat1
-/-
 mice were treated with LPS, IFN-, or IFN- (10 
ng/mL), total RNA at different time points was collected to analyze the NLRC5 relative 
expression by real-time PCR.  
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Stat pathway is activated IFNs and induce the expression of a number of genes 
that are important for anti-viral responses (O'Shea et al., 2002; Shuai and Liu, 2003).  
LPS induced TLR4 signaling activates NF-B transcription factor that regulate the 
expression of many pro-inflammatory cytokines, including IL-6, TNF-, as well as 
interferons, such as IFN-, IFN-, and IFN-. Thus, we hypothesized that TLR ligands 
induce NLRC5 expression indirectly through the secretion of NF-B activated 
cytokines. To exam our hypothesis, we stimulated Stat1
-/-
 peritoneal macrophages with 
the reported reagents that are responsible for NLRC5 induction, including LPS, IFN- or 
IFN-, and then NLRC5 expression was tested at different time points after stimulation. 
We found that Stat1 deficiency abolished the LPS, IFN-, and IFN- induced the 
NLRC5 expression (Figure 1B). We concluded that LPS induced NLRC5 expression is 
regulated by transcription factor Stat1, whose activation is mediated by NF-B activated 
cytokine release. 
 
LPS indirectly induces NLRC5 expression through type I Interferon  
To investigate if LPS induces NLRC5 expression directly through NF-B 
pathway or indirectly through cytokines stimulating other pathways, we designed a 
supernatant transfer experiment to verify the role of released cytokines in gene 
transcription induction. We treated Raw264.7 cells with or without LPS for indicated 
hours, the cells were collected to analyze the expression level of NLRC5, and the 
supernatant were transferred to untreated Raw264.7 cells for an 2 hour incubation, and  
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Figure 2. LPS-induced IFN- release activates NLRC5 transcription. (A) 
RAW264.7 cells were treated with LPS (100 ng/mL) for 1h, and then the medium was 
replaced with fresh medium after wash. NLRC5 expression at different time points was 
analyzed. (B) Cell culture supernatants from the experiment in (A) were collected and 
immediately added to untreated RAW cells. NLRC5 expression after 2 h incubation with 
the supernatants was determined by qPCR. (C) RAW264.7 cells were incubated with 
medium, LPS, LPS+anti-IFN- antibody, LPS+anti-IFN- antibody, or LPS+anti-IFN- 
antibody +anti-IFN- antibody for 6 h, RNA were collected for NLRC5 expression 
analysis. (D) After 1 h of LPS treatment, RAW264.7 cells were washed to remove the 
LPS residue and then incubated with fresh medium for 5 h. The culture supernatant were 
collected and pre-treated with LPS+anti-IFN- antibody, LPS+anti-IFN- antibody, or 
LPS+anti-IFN- antibody +anti-IFN- antibody, and then transferred to unstimulated 
cells. RNA samples were collected after 2 h incubation for analysis of NLRC5 
expression. 
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the supernatant treated cells were also collected to test NLRC5 expression. We found 
that NLRC5 mRNA was not only induced by direct LPS stimulation, but also induced by 
the treatment of supernatant from LPS treated cells (Figure 2A, B). We hypothesized 
that the molecules that released into the cell supernatant after LPS treatment led to 
NLRC5 induction. Upon TLR4-induced NF-B signaling pathway activation and tye I 
IFN signaling pathway activation, several pro-inflammatory cytokines are released from 
the cytoplasm. As Stat pathway can be activated by type I or type II interferon(Guyer et 
al., 1995; Kovarik et al., 1998; Tassiulas et al., 2004), and its activation lead to the 
transcription of the regulated genes, we purchased neutralization antibody for IFN- and 
IFN- so that the IFNs in the supernatant could be blocked. When the cells are treated 
with LPS with anti-IFN- antibody, LPS induced expression of NLRC5 was abrogated; 
however, anti-IFN- antibody did not affect the LPS-induced expression of NLRC5 
(Figure 2C). Similarly, we transferred the supernatant from LPS-treated cell culture to 
untreated cells, and found that anti-IFN- antibody blocked the induction of NLRC5, but 
the anti-IFN- antibody did not (Figure 2D). In addition, anti-IFN- antibody blocked 
almost all the induced expression of NLRC5 using the supernatant transfer protocol, 
indicating the IFN- released by the cells after LPS stimulation plays the major role to 
induce the transcription of NLRC5. NLRC5 regulates type I IFN pathway as reported 
(Kuenzel et al., 2010), so it is important to find that the transcription of NLRC5 itself is 
regulated by type I interferon. The regulated induction of NLRC5 by IFNs forms a 
negative feedback loop to prevent excessive release of type I IFN and  keeps a 
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homeostasis of the cellular microenvironment. The host would experience severe 
inflammation without the negative feedback mechanisms.  
 
NLRC5 deficiency reduced MHC class I expressed by  lymphocytes 
Several groups provided evidences to support that NLRC5 has a positive 
regulatory function in MHC class I molecule expression. One group found that both the 
MHC class I mRNA transcription level and MHC I presenting molecule increased when 
NLRC5 was overexpressed (Meissner et al., 2010). They also found that NLRC5 may 
traffic to the nucleus and bind to the promoter region of the gene encoding MHC class I 
antigen so that NLRC5 positively modulated the transcription and presentation of MHC 
class I molecule. 
We use NLRC5 deficient mice to verify the function of this gene in MHC I 
regulation, and to determine the physiological role of NLRC5 in NF-B and type I IFN 
signaling regulation. Our group generated the NLRC5 deficiency mice by constructing a 
targeting vector replacing the exon 8 of NLRC5 coding region with a designed construct 
containing a sequence encodes protein resistant to neomycine (Figure 3A). The mice 
embryonic stem cells were transfected with the construct using electroporation. The 
chimeric mice were selected for breeding. After screening for the heterozygous of 
NLRC5 knockout gene, two heterozygous mice were set as breeding pair for NLRC5 
homozygous knockout mice. The genotype of the mice were determined (Figure 3B). 
We also get the tissue from WT and NLRC5 KO mice to analyze the NLRC5 protein  
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Figure 3. Generation of NLRC5 deficient mice. (A) Schematic of NLRC5
-/-
 mice 
generation. (B) Genotyping using primers indicated in (A). (C) Detection for expression 
if NLRC5 protein in tissues isolated from WT or NLRC5
-/-
 mice by western blot. (D) 
Mendelian distribution of the pubs bred by NLRC5 heterozygous mice.  
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level in the tissue, and we found that NLRC5 is completely not expressed in NLRC5 KO 
tissues (Figure 3D), showing the success of  knocking out the gene. By observing the 
ratio of siblings of the breading pair, we found that the strain also follows the Mendelian 
ratio (Figure 3E). 
To test the MHC I expression in mice lymphocytes, we need to isolate or purify 
the spleen or thymus cells for pure population of specific cell types. The most efficient 
way is to use cell staining and flow cytometry, so that the cell populations can be gated 
by the staining of the cell type-specific cell surface markers. Cells isolated from spleen, 
thymus or lymph node were stained with fluorescence antibody of CD4, CD8 or B220, 
which are namely the cell surface markers of CD4
+
 T lymphocytes, CD8
+
 T lymphocytes 
and B lymphocytes. Cells were also stained with H2-b antibody or I-Ab for antibody, 
here we used anti-H2-b for mouse MHC I detection and anti-I-Ab for mouse MHC II 
detection. We found that H2-k
b
 expression in CD4
+
 T cells from NLRC5 deficient mice 
was significantly lower than in those from WT mice. Similar pattern were found in CD8 
positive T cells that MHC I expression in these cells of KO mice dramatically decreased 
compared with that of WT mice (Figure 4A). Consistent with the observation in T cell 
populations, B cells in NLRC5 deficient mice also express decreased level of H2-k
b
 
compared with cells from WT mice. We also check if NLRC5 deletion led to any effect 
on the MHC class II expression. Using the same method, we stained the cells with I-A
b
 
antibody, and we found that not only the T lymphocytes, but also B lymphocytes 
isolated from NLRC5
-/-
 mice expressed comparable level of MHC class II molecule, 
which is referred to I-A
b
 in this experiment, with those cells from WT mice (Figure 4B).  
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Figure 4. NLRC5 deficiency decreased MHC class I presentation in lymphocytes. 
H2-k
b
 ( mouse MHC class I) and I-A
b
 ( mouse MHC class II) staining in lymphocytes 
isolated from WT and NLRC5
-/-
 mice were tested using flow cytometry. 
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Collectively, the observations indicated that NLRC5 positively regulates the 
transcription and presentation of MHC class I molecule in mice immune cells. 
 
NLRC5 is an attenuator of TLR ligands induced NF-B activation in mice 
embryonic fibroblasts (MEF) 
Previous study found that NLRC5 interacts with IKK/, to reduce NF-B 
activity in 293T cells and IKK / was observed to be released for IKK phosphorylation 
and increased NF-B induced gene expression in Raw cells where NLRC5 is 
knockdown by siRNA (Cui et al., 2010). To validate NLRC5’s role in NF-B pathway 
in mice, we isolated MEFs from WT or NLRC5
-/-
 mice, treated the MEFs with LPS, a 
TLR4 ligand, and then examined the post-trascriptional phosphorylation level of IKK 
and MAP kinases, such as p38, JNK and ERK. As shown in Figure 5A, phosphorylation 
of IKK in NLRC5 deficient MEFs was detected to be 3-fold stronger that in WT ones 15 
minutes after LPS stimulation. However, activation levels of p38, JNK and ERK did not 
show significant difference between MEFs from WT and NLRC5
-/-
 mice (Figure 5A). 
Besides the conditions resulted from NLRC5 deficiency which affected the NF-B 
activation, we also tested whether NLRC5 deficiency led to increased expression of pro-
inflammatory cytokines at the transcriptional level. We quantified transcription level of 
mRNA of IL-6, TNF-, IL-1, and IFN- after LPS treatment using the total mRNA 
collected at different time points. The result showed that the transcription levels of IL-6, 
TNF-, and IL-1 were 0.5 to 1 fold higher in NLRC5 deficient MEFs than those in WT  
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Figure 5. NLRC5 deficiency leads to enhanced NF-B signaling after LPS 
stimulation in MEFs. (A, B) MEFs isolated from WT and NLRC5
-/-
 mice were treated 
with LPS, and cell lysates collected as indicated for western blot (A) and  total RNA was 
collected to determine the mRNA level of NF-B induced genes by real-time PCR (B). 
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Figure 5. Continued. 
 
 
 
 
 
 
 
 37 
 
ones 6 hours after LPS stimulation (Figure 5B). In contrast, the mRNA level of IFN-, 
whose activation does not depend on IKK phosphorylation but on TLR4-TRIF-TRAM 
pathway, was normal in NLRC5 deficient MEFs.  Herein, we concluded that knockout 
of NLRC5 enhances NF-B activation and increases the production of NF-B-induced 
pro-inflammatory cytokines in MEFs upon LPS stimulation, because of the lacking of 
NLRC5 to interact with IKK/ and block the IKK phosphorylation. 
 
NLRC5 deficiency increased TLR-induced pro-inflammatory response 
When the innate immune system senses the pathogenic stimulation, the pro-
inflammatory signaling is activated and leads to the expression and release of cytokines 
and chemokines which are dispensable components for inflammatory responses. The 
serious of innate immune responses induce more inflammation and recruit antigen 
presenting cells and other immune cells to defense the invasion. It would be important to 
know if NLRC5 knockout would have any effect on the cytokine release which directly 
affects the micro-environment for defending pathogens. To determine the effect of 
NLRC5 deficiency on the pro-inflammatory cytokine release after TLR stimulation, we 
treated the MEFs with ligands for different Toll like receptors, such as LPS, Poly(I:C), 
Cl097 and CpG, which are the ligands for activating TLR4, TLR3, TLR7, and TLR9 
respectively. Also a time course treatment of different TLR ligands was carried out in 
MEFs, aiming to identify if the NLRC5 inhibits NF-B signaling pathway through 
specific TLR pathway. We observed that the production of IL-6 and TNF- in NLRC5  
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Figure 6. Increased TLR ligand-induced production of pro-inflammatory cytokines 
in NLRC5-/- MEFs. WT and NLRC5
-/-
 MEFs were treated with different TLR ligands 
as indicated. The culture supernatants were analyzed for cytokine levels using ELISA.  
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deficient MEFs after different TLR ligand stimulations were all at least one fold higher 
than that of WT MEF cells at different time points (Figure 6). Especially, in the 
supernatant of NLRC5 deficient cells treated with LPS and Poly(I:C), we detected 3 to 5 
fold higher level of IL-6 production compared to normal level. Thus, NLRC5 attenuates 
TLR-induced IKK phosphorylation and NF-B regulated pro-inflammatory cytokine 
release. That is to say, NRLC5 functions as a important regulator to limit the secretion of 
pro-inflammatory cytokines and prevent severe inflammation that may lead to damage to 
the cells.  
 
NLRC5 
-/-
 embryonic fibroblasts are hyperactive in anti-viral responses to fight 
VSV 
Anti-viral signaling or type I interferon signaling is another pathway that goes 
partially through TLRs. For examples, TLR can be stimulated by viral RNA or Poly(I:C) 
and activate type I interferon signaling.  NLRC5 is able to interact with MAD5 or RIG-I 
to prevent the interaction with MAVS and block the activation of type I interferon 
signaling, which produces interferons to defend viral infection. It would be important to 
know if NLRC5 play a role in type I IFN pathway and regulate the anti-viral immunity 
in vivo. To exam if lacking of NLRC5 would affect the ability of immune responses to 
defend virus, we infected WT and NLRC5
-/-
 MEF cells with VSV-eGFP  and tested the 
type I interferon signaling at different time points. By detecting phosphorylated IRF3 
using western blot, we found that phosphorylation of IRF3 occurred about four hours 
after the cells were infected with VSV. In addition, at about eight hours after the MEFs 
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were challenged with VSV, the IRF3 phosphorylation (quantified by measuring the band 
density) in NLRC5 deficient MEFs was 2-fold higher than that in WT MEFs (Figure 
7A). We also analyzed the total IRF3 protein level in WT and NLRC5
-/-
 MEFs, and 
found comparable expression level of IRF3 in both cell groups. Moreover, the total RNA 
of MEFs after VSV-eGFP challenge was collected at indicated time points after viral 
infection, and prepared for quantitative PCR so that we could determine the IRF3 
activated transcription of type I IFNs and NF-B induced genes of TNF- and IL-6, 
which are induced by NF-B activation. Correlated with the observation that NLRC5 
deficiency increased IRF3 phosphorylation over time post viral infection, we revealed 
that expression of IFN- and IFN- in NLRC5 deficient MEFs was two folds higher 
than that in WT ones (Figure 7B).  However, little or no differences of NF-B induced 
TNF- and IL-6 expression were detected (Figure 7B), and this result is consistent with 
the early observations in Raw 264.7 cells (Cui et al., 2010). In the aspect of cytokine 
release after rival infection, NLRC5 deficient MEFs released 1.5-fold higher of IFN-b 
protein after VSV-eGFP viral infection, when we measured the protein concentration in 
the cell culture supernatant by ELISA analysis. (Figure 7C), suggesting a negative role 
of NLRC5 in IRF3 phosphorylation and anti-viral cytokine production. Next, we treated 
the MEFs with poly(I:C)/Lyo vec treatment, that is also known to activate IRF-3 
phophorylation. Similarly, significantly higher IFN- release in the supernatant of 
NLRC5 deficient cells was revealed (Figure 7C). These results convinced us that 
NLRC5 inhibits type I IFN signaling by restricting MAVS-mediated IRF3 
phosphorylation. 
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Figure 7. NLRC5 deficiency in MEFs increased IRF3-induced production of type I 
IFNs. (A) WT and NLRC5
-/-
 MEFs were treated with VSV. Cell lysates at different time 
points after viral infection were collected with low salt lysis buffer to test IRF3 
phosphorylation. (B) Total RNA of cells in (A) was harvested to exam the mRNA level 
of indicated genes using qPCR. (C) WT and NLRC5
-/-
 MEF cells were stimulated with 
TLR3 ligands or VSV for the indicated time points. The production of IFN- was 
analyzed by ELISA. 
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Figure 7. Continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
NLRC5 deficient MEFs had stronger anti-viral responses than WT MEFs 
The activation of type I interferon pathway after viral infection directly affects 
the anti-viral ability of the cells. Thus, it is essential to test the anti-viral responses in the 
NLRC5
-/-
 and WT MEFs in response of viral challenge. By utilizing the GFP labeled 
VSV-eGFP for viral infection, we were able to quantify the infection or virus by 
observing the value of GFP fluorescence in the infected cells under fluorescence 
microscopy. NLRC5
-/-
 and WT MEFs were challenged with GFP-labelled VSV and 
pictures under microscopy were taken at 24 hours after infection. WT MEFs showed 
stronger GFP fluorescence at 24 hours post infection, but NLRC5
-/-
 MEFs did not show 
any GFP at the time point (Figure 8), revealing that NLRC5
-/-
 MEF were merely infected 
by the virus at 24 hour after infection. Also, more of the WT MEFs were killed by the 
virus as showed in the phase microscopy (Figure 8). By showing that NLRC5
-/-
 cells 
were much less permissible to viral replication (GFP fluorescence) and resisant to viral 
killing (Phase) comparing to WT ones , we linked the up-regulated IRF3-responsive 
cytokine release to the enhanced antiviral immunity in the NLRC5 deficient MEF cells. 
However, when we observed the cells at 36 h after infection, we found that NLRC5
-/-
 
and WT MEFs showed similar GFP fluorescence, and the dead cell numbers were 
comparable between these two groups.  This result suggested that NLRC5 deficiency 
enhanced the anti-viral response in the early phase, but at the later time point, the 
immune response were compensated by other redundant genes that have the similar 
function as NLRC5. 
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Figure 8. NLRC5 deficiency enhanced anti-viral responses in MEFs. WT and 
NLRC5
-/-
 MEF cells were challenged with GFP-labelled VSV (MOI = 1), extent of viral 
infections or expansion indicated by GFP florescence were observed using fluorescence 
microscopy at indicated time points.  
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NLRC5 is a negative regulator of NF-B and Type I IFN pathway in peritoneal 
macrophages 
Even though MEFs express all molecules that are essential or indispensable for 
NF-B and type I IFN signaling pathway, it is not physiologically functioning as 
immune cells. Thus, the analysis of immune cells from the NLRC5 deficient mice, such 
as macrophages and dendritic cells would be crucial for our study to reveal the 
physiological role of NLRC5 in innate immunity.  We isolated peritoneal macrophages 
from the mice and treated these cells with LPS. As LPS stimulation not only activates 
NF-B pathway through TLR4 signaling, but also activates MAPK signaling pathways 
and leads to the phosphorylation or activation of ERK, JNK, as well as P38, and these 
signaling pathways are activated as fast as in the first one hour after stimulation. Thus, 
we tested the phosphorylation of IKK and MAPK signaling molecules within the first 
hour after stimulation. IKK in the NLRC5
-/-
 peritoneal macrophages was already 
activated without LPS stimulation, and the IKK phosphorylation was significantly 
increased in peritoneal macrophages isolated from NLRC5 deficient mice at 30 minutes 
and 60 minutes after LPS treatment (Figure 9A). However, MAPK signaling in WT and 
NLRC5
-/-
 cells were activated in the same pattern. NF-B signaling induced 
transcription of pro-inflammatory cytokines is another index for NF-B activation. In 
WT peritoneal cells, IL-6 and TNF- are induced by different patterns. IL-6 expression 
is activated 2 hour after LPS stimulation, and continues to increase until it  
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Figure 9. NLRC5 deficiency enhances NF-B signaling after LPS treatment in 
peritoneal macrophages. (A) WT and NLRC5
-/-
 peritoneal macrophages were 
examined for IKK phosphorylation and signaling activation after LPS (100 ng/ml) 
stimulation. Cells were lysed with low salt lysis buffer at different time points for 
western blot. (B) Total RNA was collected to analyze gene expression.  
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Figure 9. Continued. 
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reaches the peak at 8 hour after stimulation. TNF- quickly reaches the highest mRNA 
expression at 2 h after LPS stimulation and then decreases reaches the peak at 8 hour 
after stimulation. TNF- quickly reaches the highest mRNA expression at 2 h after LPS 
stimulation and then decreases (Figure 9B). Furthermore, NLRC5
-/-
 peritoneal 
macrophages released higher level of IL-6 in response to LPS compared to WT ones, 
and expressed marked higher level of TNF-, IL-1, and IFN- during early time points 
after LPS stimulation (Figure 9B). These result indicated that unlike the immune 
function in BMDCs, NLRC5 negatively regulates NF-B in murine peritoneal 
macrophages.  
 
NLRC5 deficiency enhanced TLR ligands induced cytokine release 
Besides TLR4, other TLRs such as TLR3, TLR7, TLR9 can all activated NF-B 
pathway. We would like to determine whether NLRC5 regulates only TLR4-induced 
pathway or ubiquitously regulates TLR-induced signaling. To validate the role of 
NLRC5 in pro-inflammatory response, we analyzed the cytokine production of 
peritoneal macrophage stimulated with multiple TLR agonists. WT and NLRC5
-/-
 
peritoneal macrophages both released IL-6 and TNF- as early as 2 h after ligands 
stimulation.  IL-6 production continued to increase until 24 h after stimulation. However, 
TNF- production after LPS stimulation reached the peak at 6 hour after stimulation and 
decreased afterwards. We also observed marked higher release of IL-6 in response to 
LPS (TLR4 ligand), Cl097 (TLR7 ligand), and CpG (TLR9 ligand) stimulations in 
NLRC5
-/-
 peritoneal macrophages compared to WT ones (Figure 10A). In contrast, we  
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Figure 10. NLRC5 deficient peritoneal macrophages release higher IL-6 after TLR 
ligands stimulation. (A, B) Peritoneal macrophages were stimulated with multiple TLR 
ligands, and the cell culture supernatants collected at indicated time points were 
analyzed to determine the secretion of IL-6 and TNF-.  
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did not find much difference in the TNF- release between WT and NLRC5 deficient 
cells after stimulation with Toll like receptor ligands such as LPS, CL097 and CpG 
(Figure 10B). In summary, NLRC5 is a negative regulator in NF-B signaling regulation 
and limits the pro-inflammatory cytokines production in peritoneal macrophages.  
 
NLRC5 negatively regulates NF-B pathway under a mild treatment of LPS 
Even though NLRC5 deficiency significantly enhanced NF-B activity and IL-6, 
TNF- production in MEFs, it did not lead to large difference between peritoneal 
macrophages from WT mice and those from NLRC5
 
deficient mice, especially at later 
time points. We suspected that over-dose of treatment may result in saturation of the 
signals and vein the difference. To test this hypothesis, we treated the peritoneal 
macrophages with 10 ng/ml or 100 ng/ml of LPS. Cell supernatants after 6-hour 
incubation were collected to detect IL-6 and TNF- release by ELISA. IL-6 and TNF- 
production were both increased for more than 2 folds in the NLRC5
-/-
 cells compared to 
WT cells when the cells were treated with lower dose (10 ng/ml) of LPS. However, 
when the cells were treated with higher dose (100 ng/ml) of LPS, we only found mild 
difference in IL-6 release, but not in TNF- release (Figure 11). The results suggested 
that NLRC5 deficiency significantly enhanced pro-inflammatory cytokine release in 
peritoneal macrophages in response of mild stimulation of TLR ligand. It indicated that 
as a negative regulator, NLRC5 only affects the physiology response in the early time 
after treatment, and a lower dose of stimulations. NLRC5 may play a role to eliminate 
unnecessary signals for NF-B activation to prevent auto-inflammatory diseases, and it  
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Figure 11. NLRC5 inhibits NF-B signaling pathway under low dose of LPS in 
peritoneal macrophages. WT and NLRC5
-/-
 peritoneal macrophages were treated with 
low dose (10 ng/ml) or high (100 ng/ml) dose of LPS for 6 h.  IL-6 and TNF- secretion 
in supernatants were analyzed by ELISA. 
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does not stop inflammation when the immune system need inflammatory response to 
defend pathogens. 
 
NLRC5 deficiency enhanced the type I interferon signaling and anti-viral responses 
in peritoneal macrophages 
We infected peritoneal macrophages with GFP labelled VSV to demonstrate the 
physiological function of NLRC5 in antiviral responses or type I IFN signaling pathway 
in these type of cells. Phosphorylation level of IRF3 initiated 4 h after viral infection in 
NLRC5 deficient cells. By contrast, IRF3 phosphorylation level in WT cells could not be 
detected as late as 8 h after VSV-eGFP infection. In addition, we detected increased 
IRF3 phosphorylation in NLRC5
-/-
 peritoneal macrophages (Figure12A), which further 
supported the point that NLRC5 attenuates antiviral capability by preventing activity of 
antiviral response after virus infection in these cells. . And the GFP positive cells, which 
are cells infected by the VSV-eGFP were observed more in WT cells rather than in 
NLRC5
-/-
 cells (Figure 12B), indicating that NLRC5
-/-
 peritoneal macrophages have 
enhanced antiviral response activity compared to WT cells. 
To elucidate that NLRC5 inhibit type I interferon pathway through RIG-I and 
MDA5, peritoneal macrophages were challenged with VSV-eGFP, Poly(I:C).Lyo Vec 
(intracellular dsRNA ) that signal through RIG-I/MDA5), and TLR ligands (LPS, 
Poly(I:C), whose signaling is independent on RIG-I/MDA5. IFN- release was  
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Figure 12. NLRC5 deficiency enhanced antiviral responses in peritoneal 
macrophages. (A) Peritoneal macrophages from WT and NLRC5
-/-
 mice were infected 
with VSV-eGFP. Cell lysates at different time after infection were collected for western 
blot. (B) Cells were incubated with VSV-eGFP (MOI = 10), then extent of virus 
proliferation was observed at 24 h after infection using microscopy. (C) NLRC5
-/-
 and 
WT peritoneal macrophages were stimulated with indicated ligands, and the culture 
supernatants at different time points were used to measure the IIFN- production by 
ELISA. 
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Figure 12. Continued. 
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significantly higher in cells from NLRC5 deficient mice in response to  a type of dsRNA 
virus named VSV-eGFP or a ligand for RIG-I called intracellular Poly (I:C). However, 
IFN- secretion level in the culture supernatant was normal when they were treated with 
ligands for TLR4 or TLR3, namely LPS or poly(I:C),  which activates TLR4 or TLR3, 
respectively (Figure 12C). In conclusion, NLRC5 inhibits RLR-mediated type I 
interferon signaling pathway. 
  
NLRC5 deficient peritoneal macrophages have normal inflammasome activity after 
stimulation with LPS and ATP 
We observed that NLRC5 deficiency led to increased pro-IL-1 transcription 
after TLR ligands stimulation in both MEFs and peritoneal macrophages. NLRC5 is also 
reported to positively regulate NLRP3 inflammasome(Davis et al., 2011).  According to 
the mechanism of NLRP3 inflammasome activation, pro-IL-1 need to be transcribed by 
NF-B activation and then pro-IL-1 is cleaved by activated caspase-1 into mature IL-
1. Caspase-1 can be activated by various inducers, for instance, ATP can lead to the 
oligomerization of ASC and NLRP3 forming inflammasome and cleave caspase-1 into 
activated caspase-1 (P20). To determine the effect of NLRC5 deficiency in NLRP3 
inflammasome activation, we treated the WT and NLRC5
-/-
 peritoneal macrophages with 
LPS for 3 hours and then the cells were pulsed by ATP for 1 h. Cell supernatants were 
then collected to detect IL-1 release after stimulation. NLRC5-/- peritoneal 
macrophages released comparable level of IL-1 with the WT ones in response of LPS+  
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Figure 13. NLRC5 deficient peritoneal macrophages have normal inflammasome 
activity. WT and NLRC5
-/-
 peritoneal macrophages were treated with LPS for 6 h and 
then with 0.5mM ATP for 1 h. IL-1 production was measured by ELISA.  
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ATP stimulation (Figure 13). These data revealed that NLRC5 deficiency did not 
influence the NLRP3 inflammasome activation in response of LPS+ATP. 
 
NLRC5 deficiency pathway in bone marrow-derived macrophages enhances both 
NF-B and Type I IFN signaling 
To determine whether knockout of mouse NLRC5 expression also contributes to 
enhanced NF-B signaling activation in other primary immune cells, we isolated bone 
marrow-derived macrophages (BMMs) and treated the cells with LPS. The result 
showed that the phosphorylation level of the TLR-induced signaling molecule IKK is 
markedly higher in BMMs from NLRC5 deficient mice comparing to those from WT 
mice (Figure 14A). However, the phosphorylation of JNK, ERK and P38 in the NLRC5
-
/-
 BMMs had no difference from that in WT BMMs (Figure 14A). Thus, LPS induced 
MAPK signaling pathways activation was comparable between NLRC5
-/-
 and WT 
BMMs. When the BMMs from the mice were stimulated with LPS for different time 
points, IL-6 secretion from NLRC5
-/-
 BMMs was significantly higher than that from WT 
ones (figure 14B). And we saw the most significant difference in the cytokine release at 
6 hour and 12 hour after LPS stimulation, but not at 24 hour time point, suggesting that 
NLRC5 negatively regulates NF-B pathway in early time points in response of TLR 
ligand stimulations. We also stimulate the BMMs with other TLR ligands, and found 
markedly increased release of IL-6 in NLRC5
-/- 
BMMs after CpG or Cl097 stimulation 
at different time points (Figure 14B). We concluded that NLRC5 deficiency in BMMs 
significantly increased TLR ligands induced pro-inflammatory cytokine release.  
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Figure 14. NLRC5 deficiency in BMMs increased TLR ligand-induced NF-B 
signaling. (A) WT and NLRC5
-/-
 BMMs were stimulated with TLR4 ligand LPS, and 
the cell lysates at indicated time points were prepared for western blot. (B) BMMs were 
treated with multiple TLR ligands such as LPS, CpG or CL-097, and the culture 
supernatants collected at indicated time were collected for ELISA analyses.  
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NLRC5 deficiency in BMMs increased type I IFN signaling 
We also stimulated the BMMs with GFP-labelled VSV, so that the role of 
NLRC5 deficiency in dsRNA virus-induced anti-viral or type I IFN signaling of BMMs 
can be determined. Phosphorylation of IRF3 in BMMs was activated about 4 h after 
VSV infection in WT BMMs, and the phosphorylation accumulated upon time. We also 
detected increased phosphorylation level of the signaling molecule IRF3 at 6 h after the 
macrophages were infected with the virus in NLRC5
-/-
 group (Figure 15A). Adding more 
evidence that NLRC5 inhibits antiviral responses, we evaluated the anti-viral response 
after infection with VSV-eGFP or transfected with Poly(I:C) by examining the viral 
infection-induced production of IFN- by ELISA. NLRC5-/- BMMs secreted higher level 
of IFN- compared to WT ones after stimulations activated through RIG-I/MDA5 
pathway such as VSV-eGFP or Poly(I:C)/Lyo Vec at 24 h after VSV-eGFP infection, 
but not at 8h or 12 h post infection(Figure 15B).  This time frame may depend on the 
process of viral infection, because we usually see GFP 24 hours after VSV-eGFP 
infection. Nevertheless, Poly(I:C) treatments did not make a difference for antiviral 
cytokine release between WT and NLRC5 KO BMMs (Figure 15B). Therefore, NLRC5 
is also required for negative regulation of both TLR-induced NF-B and viral infection 
or RIG-I/MAD5 mediated type I interferon pathway in bone marrow-derived 
macrophages. Herein, we concluded that NLRC5 deletion enhances not only NF-B 
signaling pathway but also type I interferon pathway in macrophages. 
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Figure 15. NLRC5 ablation in BMMs enhanced type I IFN signaling after viral 
infection. (A) WT and NLRC5
-/-
 BMMs were challenged with GFP-labelled VSV. At 
indicated time points after infection as mentioned, the cell lysates were collected to test 
the phosphorylation level of signaling molecule IRF3 by western blot. (B) WT and 
NLRC5
-/-
 BMMs were challenged with inducers of type I IFN pathway.  ELISA was 
carried out using the culture supernatants to detect IFN- production. 
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NLRC5 deficiency did not lead to difference in TLR ligands induced NF-B 
signaling 
Kumar’s group using their NLRC5 knockout mice, tested NLRC5’s function in 
NF-B signaling in bone marrow derived or differentiated macrophages, and they found 
that NLRC5-/- and WT BMDC responded to the NF-B activator with no differences 
(Kumar et al., 2011). In our study, we used the newly generated NLRC5 deficient mice 
that targeting the Exon 8, encoding the functional domain of the protein. We found that 
absence of NLRC5 led to stronger NF-B signaling in response of multiple TLR ligands. 
We also generated BMDCs, and treated the cells with multiple categories of TLR 
agonists, such as LPS, CpG, Cl097, and Pam3scK. However, NLRC5
-/-
 and WT BMDCs 
released comparable level of pro-inflammatory cytokine IL-6 and TNF-. And we also 
tested IL-12 release, which did not show much difference between WT and NLRC5
-/-
 
cells as well (Figure 16). Thus, in BMDCs, NLRC5 does not play an important role in 
regulating NF-B signaling in response of TLR signaling activation. This result may be 
explained by the cell type dependent manner, that specific type of cells achieves the 
signaling activation through different mechanisms. This would be further discussed in 
the discussion. 
 
NLRC5 negatively regulates NF-B and Type I IFN pathways in vivo 
We next sought to determine the function of NLRC5 in vivo in LPS-induced 
septic shock. NLRC5
-/-
 and WT mice were intraperitoneally injected with a high dose 
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Figure 16. Normal TLR-induced cytokine release in NLRC5
-/- 
BMDCs. WT and 
Nlrc5
-/- 
 BMDCs were treated with indicated TLR ligands for indicated times. IL-6, 
TNF-, and IL-12 released in the supernatant were determined by ELISA. 
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of Escherichia coli LPS, and then the mice were monitored for their survival after septic 
challenge and the mice plasma were collected in early time points after LPS challenge. 
From the experiment, we observed that more than 80% of the NLRC5 deficient mice 
died within 48 hours, whereas 60% WT mice remained live (Figure17A). Even though 
there is a slight difference in survival between WT and KO group of mice, the difference 
is not statistically significant (Figure 17A). We also observed significantly higher serum 
IL-6 in NLRC5 KO mice (Figure 17B). Yet, this significant difference in plasma IL-6 
level disappeared 3 h after LPS treatment. Moreover, the secretion of TNF- in the 
plasma was comparable between NLRC5 deficient and WT mice (data not shown). 
These in vivo data give basis for the statement that NLRC5 negatively regulates NF-B 
induced IL-6 production in the early phase during LPS-induced septic shock, however 
this effect fades as the treatment reached later phase. 
 
NLRC5 deficiency did not make difference in anti-viral responses in response of in 
vivo viral infection 
Even though NLRC5 deficiency enhanced type I IFN signaling and anti-viral 
responses in mouse fibroblasts and macrophages, it is still important to know whether 
the anti-viral ability of the mice would be affected in absent of the gene expression of 
NLRC5. To test whether NLRC5 knockout alternate survival after viral infection, we 
injected VSV-eGFP into NLRC5
-/-
 and WT mice using tail vein (i.v) injection and then 
monitored their survival. Mice plasma was collected at different time points to inspect 
the viral infection and immune response reflecting by cytokine release in the plasma.  
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Figure 17. Functional role of NLRC5 in innate immunity under physiological 
conditions. (A) WT and NLRC5
-/-
 mice, five mice for each group were injected with 
LPS, and the mice survival after challenge was observed. (B) Mouse sera were collected 
from WT and Nlrc5-/- mice when the mice were intraperitoneally injected with LPS for 
1 h. 
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NLRC5
-/-
 mice did not die under the low dose of virus infection as well as WT mice. We 
detected appreciable differences not in serum viral titers (Figure 18A, B), but in the IFN-
 level released in to the plasma at 6 hour after VSV-eGFP infection (Figure 18A). In 
brief, NLRC5
-/-
 mice release significantly higher level of anti-viral interferon at the early 
phase post viral infection. However, this difference did not sustain to the later phase of 
infection, and did not make difference in defending the viral invasion. Together, these 
results suggest that NLRC5 knockout promotes type I IFN pathway activity especially at 
a time frame when innate immunity is initiated, or relative early time in mice, but merely 
make difference for antiviral responses. 
 
Discussion 
 
Negative regulation of inflammatory pathways 
Innate receptors (TLRs, NLRs and RLRs) activation triggers a cascade of 
signaling pathways (NF-B activation, type I IFN activation) and leads to the production 
of various inflammatory cytokines such as IL-6, TNF- and type I IFN, which have 
profound effects on the inflammation and tissue destruction. Plenty of evidence shows 
that dysregulation of these pro-inflammatory genes lead to unwanted or even fatal effect 
on the host by the over-activation of the innate immune system. In addition, such 
proinflammatory cytokine milieu has been shown to facilitate tumor development and 
progression. For example, production of IL-1 will lead to the differentiation of Th17 
cells around tumors (Miyahara et al., 2008), and IL-17 in the tumor microenvironment  
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Figure 18. Increased type I IFN release in NLRC5
-/-
 mice after viral infection.  (A) 
IFN- release in the serum of WT and NLRC5-/- mice at 6 h after they were challenged 
with VSV-eGFP using i.v. injection. (B) Serum collected from WT and NLRC5
-/-
 mice 
at indicated time points after viral injection were used for virus titration. 
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produced by activation of Th17 cells can induce angiogenesis and help tumor cell 
survive(Chung et al., 2013).  
 
NLRC5 in negative regulating NF-B and anti-viral immunity 
Many of the negative regulatory proteins themselves are transcriptional targets of 
NF-B or IRFs, thus, a negative feedback loop is formed. NF-B targeted A20, CYLD 
and DUBA are typical examples of negative feedback molecules. We initially observed 
the up-regulation of NLRC5 in both human cell lines and mouse primary macrophages is 
controlled by TLR4 induced NF-B activity, suggesting a possible classical feedback 
loop. But there are possibilities that a secondary signaling pathway triggered by NF-B 
induced products could be the real cause of induction of NLRC5. By promoter analysis, 
we and others found that NLRC5 promoter has a conserved STAT binding motif. It is 
possible that the STAT proteins induced by IFN-/IFN- could induce the transcription 
of NLRC5. Both IFNs are induced by LPS induced NF-B activation. By using STAT1 
KO peritoneal macrophages, we found decisively that LPS induced NLRC5 expression 
was completely abolished in STAT1 KO cells indicating that the induction of NLRC5 
observed in response of  LPS stimulation is a secondary effect of IFNs activated by NF-
B pathway, though STAT1 dependent signaling pathway. The molecular mechanisms 
revealed provided another type of negative feedback type that the regulatory protein is 
induced by a secondary pathway triggered by NF-B activation.  
Previous studies indicate that NLRC5 can negatively regulate NF-B signaling 
pathway and anti-virus pathway at IKK level and RIG-I level respectively(Cui et al., 
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2010), but in vivo function of NLRC5 is not yet determined. Here, by generating NLRC5 
KO mice, we found that NLRC5 regulates NF-B activation and type I IFN production 
in a cell-type specific manner. We examined WT and KO cells include MEFs, peritoneal 
macrophages, BMDCs, BMMs, and we found that the most marked difference between 
WT and KO group is in MEFs. In macrophages, the difference is there but modest 
whereas in BMDCs, there is no difference between WT and KO group. The cell type 
specificity may due to several reasons: one is the mRNA transcription levels of the 
coding region of NLRC5 in these different tissues or different cell types vary. Indeed, 
the expression of NLRC5 differs dramatically among different cell types (Benko et al., 
2010; Cui et al., 2010; Kuenzel et al., 2010). Another mechanism is that different cell 
types may utilize different molecular mechanisms for a particular pathway regulation. 
For example, TAK1 is shown to be a critical adaptor protein for NF-B activation in 
MEF cells as well as in T cells and in B cells. However, one recent study found that 
TAK1 is not required but instead, exhibits negative effects in cell types such as 
neutrophils in vivo(Ajibade et al., 2012). Another example is TANK. Although it is 
reported to be an activator of IRF3 and NF-B, it has been recently shown in vivo that 
TANK KO mice have enhanced NF-B signaling by a possible in vivo role of promoting 
the ubiquitination and degradation of TRAF6 in response to TLR ligand 
binding(Kawagoe et al., 2009). Based on such observations, we contended that NLRC5 
inhibits NF-B signaling pathway induced by TLR ligands and type I IFN signaling 
induced by viral infection in MEFs and in a lesser extent in primary immune cells, 
especially macrophages, but not DCs. There are other groups developed NLRC5 KO 
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mice independently by targeting exon 4 and they reported no effect of NLRC5 in 
regulating inflammatory cytokines in macrophages and dendritic cells when the they are 
treated with TLR ligands or pathogens such as HSV-1, L. monoctogenes and NDV 
(Kumar et al., 2011). The experiments which are performed in BMDCs in our hand 
come out to be similar with their findings showing almost no difference between WT 
and NLRC5 KO cells. However, we truly found that in BMMs, there is significant 
difference after LPS or poly (I:C) challenge. The discrepancy may be resolved by three 
reasons. First, targeting different exons may have different outcomes in NLRC5 KO 
cells (exon 4 versus exon 8 deletion). Although mechanisms are not clear, there are 
examples of slight different phenotypes between KO mice with different exon targeting 
strategies such as SMAD3 KO mice generated by different groups. Secondly, a possible 
difference in the mouse background could also affect the outcome of in vivo 
experimental results. Although we backcrossed our NLRC5 KO mice with B6 
background mice for more than 10 generations, it is still possible that traces of 129 
background sequences in the genome will affect the experimental results. The third 
reason may due to different dose of LPS stimulation. In our hands, we use low dose of 
LPS whereas in other studies, high LPS dose (10 times higher compared to that we used) 
is used and may saturate the system.  The saturated doses of LPS might overcome the 
effects of NLRC5 on the production of proinflammatory in WT and NLRC5-deficient 
cells. In addition, we found that ablation of NLRC5 showed more obvious difference in 
IL-6 mRNA trascription in both the cell types we looked at, namely MEFs and 
macrophages. However, the increase of another proinflammatory cytokine TNF- is 
 70 
 
much less obvious in macrophages. This might results from the multiple layers of TNF-
 regulation. Cytokines such as pro-IL-1and TNF- are subjected to 
posttranscriptional regulation at different levels such as the mRNA stability and the 
protein translation(Han and Ulevitch, 2005). Such kind of discrepancy is common in 
immunology studies. Similarly, our group and others found that both NLRX1 
knockdown or NLRX1 deletion led to dramatic change in the cytokine level of IL-6 but 
not another proinflammatory cytokine TNF-, although the NF-B activation 
mechanism is generally considered similar in vitro. NLRX1 knockdown leads to 
significantly higher IL-6 secretion level in the serum than the serum IL-6 detected in the 
WT mice after the mice were injected with LPS. However, the serum TNF- level in the 
challenged NLRX1 knockdown mice was normal. It is possible that although the stimuli 
go through the common IKK-NF-B complexes, the consequences of transcription of 
target genes may often be different with each other and more often than not are cell type 
specific, depending on some quantitative and qualitative properties of signaling in 
different cell types.  
The functionally redundant negative regulators at the similar molecular level 
(IKK) such as CUEDC2 and NLRX1 in inhibiting NF-B signaling may also contribute 
to the phenotype difference between in vitro and in vivo studies. In vitro studies often 
utilize knockdown assays and measure the cytokine immediately after gene knockdown 
by siRNAs or shRNAs. The cells barely have time to compensate for loss of one 
particular gene product. But in vivo gene deletion happens at the embryonic stage and 
the mice have plenty of time (6-8 weeks) to find a redundant molecular pathway to 
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compensate for the loss of one particular gene product. In this perspective, we generated 
NLRC5 KO and NLRX1 knockdown mice to study the possible compensation in vivo. 
Indeed, we found that in mice lack both molecules, the increase in pro-inflammatory 
cytokines such as IL-6 are significantly higher than single molecule deficient mice. This 
provides a new molecular mechanism of the possibility of compensation of functionally 
redundant genes in vivo. After all, there are still plenty of reports that cannot agree with 
each other in the field for unclear reasons. One example is that one group showed that 
NLRX1 KO mice exhibited increased level of IFN- expression after infection with 
influenza virus(Allen et al., 2011),  but other scientists observed NLRX1 does not have 
function in type I IFN signaling (Rebsamen et al., 2011). Thus, further studies have 
signaling to be performed to illustrate the exact role of one particular molecule in vivo 
before they can be applied to clinical studies. 
In all, we showed that IFN-mediated Stat1 signaling is required to activate the 
transcription of NLRC5 mRNA when IFNs are sensed by the receptors. NLRC5 
deficiency decreased the expression and presentation of MHC Class I genes majorly in T 
cells and in a lesser extent in other cells. NLRC5 deficiency enhanced LPS or VSV 
infection induced NF-B signaling and type I IFN signaling pathways in a cell type 
dependent manner. 
 
NLRC5 in MHC class I regulation 
MHC class I molecules is comprised of a polymorphic heavy chain and a shared 
light chain (2m). In human, heavy chains include HLA-A, HLA-B and HLA-C classes, 
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while in mice, heavy chains include H2-K, H2-D and H2-L classes. In human, the MHC 
class I heavy chain genes are located in a region of chromosome 6, where a number of 
severe diseases such as diabetes, asthma is associated to (Lie and Thorsby, 2005). Thus, 
MHC class I regulation must be very important for human diseases. Initially, studies 
found that one member of NLRC proteins which is called CIITA, when overexpressed in 
vitro, can activate the expression and presentation of MHC class I molecule expression 
(Martin et al., 1997; Williams et al., 2003). Due to the high homology of NLRC5 and 
CIITA as well as NLRC5 nuclear localization when overexpressed, it is intriguing to 
determine if NLRC5 can also regulate the expression of MHC class I gene. Indeed, it 
was reported that over-expression of WT NLRC5 can induce MHC class I genes such as 
HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, 2m expression as well as genes 
responsible for MHC class I processing and presentation such as TAP1 and LMP2 
(Meissner et al., 2010), however, the NLRC5 mutant lacking the NLS sequence failed to 
do so. The up-regulation of MHC molecules is restricted to MHCI instead of MHCII 
indicating that NLRC5 specifically activates MHC class I genes. In vitro siRNA 
knockdown of NLRC5 assays also confirmed the function (Meissner et al., 2010). But 
the in vivo evidence of NLRC5 regulating MHC I molecules is still lacking. The fact that 
CIITA deficient mice do not have defects in expression of MHCI indicating a possible in 
vitro artifacts. By generating NLRC5 knockout mice via replacing exon 8 in the cDNA 
of NLRC5 gene, we used FACS analysis to determine MHC class I presentation on the 
surface mouse lymphocytes. We found that NLRC5 positively regulates MHC class I 
expression because we observed that in NLRC5 knockout mice, the expression or 
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presentation level of H2-K (B6 background) is defective in many cell types including 
CD4+ T cells, CD8+ T cells, B cells, DCs, macrophages and neutrophils. The biggest 
difference of expression is in T cells whereas the difference is milder in cDCs, B cells, 
macrophages and neutrophils. This result indicated that NLRC5 specifically regulate 
MHC class I expression in vivo in a cell type specific manner. However, the expression 
of MHC class II molecules were comparable between WT and knockout group in all the 
cell types examined. In the meantime, an independent study using NLRC5
-/-
 mice 
obtained through targeting the  exon 4 on cDNA of the coding region for NLRC5 
confirmed our observation in vivo by showing NLRC5 deficient T, NKT, NK and T 
cells have dramatically impaired MHC class I molecule expression and are also 
defective to be induced by IFN- (Biswas et al., 2012; Robbins et al., 2012; Staehli et al., 
2012). Because MHC class I complex is very critical for the recognition of antigens by 
CD8+ T cells, the defective MHC class I expression in the NLRC5 deficient mice could 
lead to a defective CD8 T cells response. Consistent with this notion, the CD8+ T cell 
activation were indeed reduced in NLRC5 KO mice when challenged with specific 
antigen (Yao et al., 2012) and was not able to clear the intracellular pathogen L. 
monocytogenes in vivo(Staehli et al., 2012; Yao et al., 2012).  Because tumor cells are 
often down-regulating MHC class I to avoid immune surveillance, it is possible that 
NLRC5 down-regulation is utilized by tumor cells. Firstly, it is found to be true that the 
expression of NLRC5 is very low in tumor cell lines  related to the dysregulation of T 
and B cells (Staehli et al., 2012), indicating certain types of tumors are using such 
mechanisms to avoid being attacked by CD8+ T cells. We are looking for tumors which 
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have NLRC5 mutations in tumor cells by sequencing exons of NLRC5 in tumor cells. 
Until now, only very few mutations were found in NLRC5 coding regions in tumor cells. 
The future work should increase the sample size and also perform regulatory regions of 
NLRC5 sequencing given the fact that the sequencing technologies are growing super-
fast during these years. It will be important to investigate whether NLRC5-MHCI axis is 
associated with anti-tumor immunity, anti-viral immunity and anti-allograft 
transplantation. 
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CHAPTER III 
FUNCTIONAL CHARACTERIZATION OF DDX46 IN  
NLRP3 INFLAMMASOME ACTIVATION 
 
Introduction 
 
Inflammasome 
The concept of inflammasome was first introduced by Tschopp and his 
colleagues in 2002(Martinon et al., 2002). Inflammasome is a huge protein complex that 
forms in the cytoplasm to serve as a platform to recruit and activate pro-caspase-1. 
Among the caspases, caspase-1 activation is the most well characterized in 
inflammasome activation and the consequence of caspase-1 activation is proteolytic 
cleavage of pro-IL-1 and pro-IL-18 and release of mature cytokine into the 
extracellular environment(Cerretti et al., 1992; Thornberry et al., 1992). It has become 
clear now that there are distinct inflammasomes which are scaffolded by different 
proteins, mainly by members of NLR family members containing nucleotide-binding 
domain (NBD) and leucin-rich repeats (LRRs). The characterized inflammsome includes: 
NLRP1, NLRP2, NLRP3, NLRP4, NLRP5, NLRP6, NLRP9, NLRP10, NLRP12, 
NLRP14, NLRC4, AIM2 inflammasomes.  
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NLRP3 inflammasome 
NLRP3 was first reported in 2002 that it activates caspase-1, and later described 
to be responsible for autoinflammatory periodic fevers, for example, Muck-Wells 
syndrome(Martinon et al., 2009; Strowig et al., 2012). Unlike NLRP1, NLRC4 
inflammasome, NLRP3 is not constitutively expressed in most unstimulated cells. 
NLRP3 expression can be induced by PAMP detection through TLR activation and NF-
B signaling pathway. However, NLRP3 activation requires a second signal to induce 
oligomerization. These secondary stimuli include crystalline stimulations (alum, uric 
acid crystals, silica) (Dostert et al., 2008; Eisenbarth et al., 2008; Martinon et al., 2006), 
ATP (Mariathasan et al., 2006), viral infections (Ichinohe et al., 2009), fungal products 
(Joly and Sutterwala, 2010), bacterial nucleotides (Kanneganti et al., 2006; Muruve et 
al., 2008; Sander et al., 2011) and numerous toxins (Vance et al., 2009). Since there are 
so many inducers for NLRP3 inflammasome activation, it is not clear how a single 
molecular mechanism can unify all the different ligands to activate the inflammasome. 
After all, these stimulations usually lead to calcium or potassium efflux, ROS change. 
There is a big unsolved problem that how NLRP3 is activated by these DAMP signals. 
In general, stimuli can be divided into two categories, crystalline and noncrystalline. For 
crystalline stimuli, the common mechanism is based on the lysosomal destabilization 
that results in release of enzymes such as cathepsin B and in turn activates 
NLRP3(Hornung et al., 2008). For noncrystalline NLRP3 activation, GBP5 is required 
for optimal NLRP3 activation and oligomerization (Shenoy et al., 2012). Another model 
for NLRP3 activation proposes that reactive oxygen specis (ROS) generated by 
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NADPH-oxidase during phagocytosis or by mitochondria can dissociate TXNIP from 
thioredoxin and TXNIP can be a ligand for NLRP3(Zhou et al., 2010). But models 
regarding ROS hypothesis remains highly controversial by Txnip KO or Panx1 KO 
studies showing normal NLRP3 activation in knockout mice(Masters et al., 2010; Qu et 
al., 2011). But in all cases, the exact detailed molecular mechanism is still lacking. The 
post-translational modification of NLRP3 is related to its activation. Ubiquitination of 
inflammasome complex lead to inflammasome degradation, accordingly, 
deubiquitination of NLRP3 would prevent inflammasome from degradation, so that 
inflammasome is activated. So far, the only reported post-translational modification of 
NLRP3 is deubiquitination by BRCC3(Py et al., 2013). 
 
DDX/DHX family members and DNA/RNA sensors 
Equal effort has been focused on finding the activating sensor of inflammasome 
in response of different inflammasome stimulations. DHX33 has been found to directly 
bind to double strand RNA and activate NLRP3 being an example of sensors that might 
detect different categories of PAMPs and DAMPs to activate NLRP3 inflammasome 
(Mitoma et al., 2013). Thus, it is probable that other members of the DDX and DHX 
gene family members can be sensors of different kinds of nucleic acid because they have 
conserved helicase domain sequences to serve as RNA helicases. Until now, there are 36 
members of DEAD family and 14 members of the DEAH family to be putative nucleic 
acid helicases. The DHX members are involved in pre-mRNA splicing such as DHX15, 
DHX16 and DHX38. It is interesting that some DDX members are dysregulated in 
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cancer involving in chromosomal translocations. And consistently, some DNA helicase 
mutations are found to be important increasing the incidence of cancer types (Van 
Brabant et al., 2000). But the functions of DDX and DHX family members in immunity 
are just being studied. Due to their nucleic acid binding ability, DDX and DHX family 
proteins are potential DNA/RNA sensors in the cytoplasm and provide specificity to 
different stimuli. Actually, RIG-I (DDX58) and LGP2 (DHX58) both belong to the 
family and are famous RNA sensors in type I IFN pathways (Beutler et al., 2007). And 
by biochemical purification of CpG DNA binding proteins, DHX36 and DHX9 are 
found to be sensors of CpGA and CpGB in pDC cells (Kim et al., 2010). Here, by 
screening inflammasome activation in 293-ASC-caspase-1-IL-1 cells, we found that 
DDX46 is involved in inflammasome activation. By ligand screening, we further 
identified that DDX46 can be cleaved upon crystalline stimulation and the cleaved form 
of DDX46 can significantly bridge the interaction of NLRP3 and ASC to activate 
caspase-1, leading to optimal NLRP3 inflammasome activation and IL-1 production in 
vitro.  
 
Materials and Methods 
 
Cell lines 
293T-caspase-1-ASC cell line has been described previously (Yu et al., 2007; Yu 
et al., 2006). Stable 293T-caspase-1-ASC-pro-IL1β cell line was obtained by 
transfecting 293T-caspase-1-ASC with expression plasmid pMSCVgfp-pro-IL1β. Stable 
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cell lines were generated after multiple cell-sorting by flow cytometry over a period of 
one month. 293T-caspase-1-ASC-pro-IL-1-NLRP3 cells were generated by infecting 
the 293T-caspase-1-ASC-pro-IL1β cells with lentivirus expressing NLRP3. Expression 
of NLRP3 of the constructed cell line was verified by western blot, and the 
inflammasome activation system utilizing this cell line was tested and proved to be 
effective for inflammasome activation. 
 
ELISA for human IL-1 
Put all samples and reagents to room temperature. Make sure to duplicate each 
samples and standard curve. Prepare standard dilutions and samples using sample 
diluents as indicated by manufacturer. Get the pre-coated plate strips as needed. Add 200 
µL of Standard dilution, control or sample to each well. Cover the strip with a plate 
sealer, and incubate at room temperature for 2 hours. Wash the plate for 3 times. 
Then add 200 µL of Conjugate to each well. For samples of cell culture supernatant: 
cover the plate with a new plate sealer, and incubate the plate at room temperature for 1 
hour.  Aspirate and wash 3 times. Add 200 µL of substrate solution to each well. 
Incubate the plate at room temperature for 20 minutes in dark. Finally, add 50 µL of stop 
buffer to each well. Read at 450 nm with a plate reader within 30 minutes. Set 
wavelength correction to 570 nm.  
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Protein precipitation of cell culture supernatants 
Cells were grown in non-serum medium with specific ligands as indicated, cell 
culture supernatants were collected at indicated time points. Proteins in the cell culture 
supernatants were precipitated with an equal volume of methanol and 0.25 volume of 
chloroform. Then the samples were vortexed and centrifuged at 16000g for 15 min. The 
upper phase was discarded and the precipitate was washed with one volume of methanol 
followed by centrifugation for 15 min at 16,000g. The upper phase was discarded. The 
protein pellet was dried in 55 °C for 10 min. Then the pellet was resuspended in 4xSDS 
protein loading buffer and boiled for 5 min at 100 °C. The presence of caspase-1 and IL-
1 was then analyzed by western blot. 
 
Immunoprecipitation 
After cell stimulation, cells lysates were collected to test the interaction using 
low salt lysis buffer with protease and phosphatase inhibitors. Place the lysates on the 
shaker in 4 degree for 20 min to make sure the proteins are completely released into the 
buffer. Spin down the cell debris or other reagents by centrifugation at 12,000 g for 5 
minutes. The supernatant were collected and used for protein concentration 
quantification. These were pre-washed with the beads with secondary antibody of 
choice. They were tumbled at 4°C for 30 minutes. Then remove the washing supernatant 
and add primary antibody to the tubes. This was tumbled overnight at 4°C. On the 
second day, the secondary antibody was then added and tumbled for 2 hours at 4°C. This 
was spun down at 8,200 g 5min. Then remove the supernatant, leaving the agarose 
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beads. The left beads were resuspended in 300μl of low salt lysis buffer to wash and 
spun down at 8,200 g. Repeat for two times for a total of three washes. Finally the 
agrose beads were spun down with the supernatant removed. 15 μl of 4xSDS protein 
loading buffer was added to each sample for SDS-PAGE gel running.  
 
siRNA mediated knockdown by electroporation 
Add the entire tube of supplement solution into Nucleofector® Solution. Pre-load 
12-well plates with 1 ml of indicated culture media. Pre-warm the medium within the 
plates in a 37°C/5% CO2 incubator. To prepare the cells, quantify a small aliquot of the 
cells to determine the cell density. Prepare 1 x 10
6
 cells for each sample, and centrifuge 
the cells at 90xg for 10 minutes at room temperature. Remove cell supernatant 
thoroughly and resuspend the cell pellet with 100 μl of room-temperature Nucleofector® 
Solution for each sample. Handle the experiment quickly enough to avoid exposing the 
cells in Nucleofector® Solution for more than twenty minutes so that the cell viability 
and transfection efficiency are not affected. Add 0.5 μg DNA or 30-300 nM siRNA into 
the cells suspension with nucleofector solution. Load the mixture into certified cuvette to 
cover the bottom of the cuvette and make sure the liquid is without air bubbles, and close 
the lid of the cuvette. Use specifically Nucleofector® Program U-001 for high viability 
or V-001 for high expression level. Insert the loaded cuvette into the Nucleofector® 
Cuvette Holder and run the desired program pressing the X-button. After taking out the 
cuvette, immediately add ~500 μl of the pre-warmed culture medium to the cuvette and 
gently transfer the cells into the prepared plate using the supplied pipetes. THP-1 cells 
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can be differentiated in differentiation medium immediately after Nucleofection®. 
Incubate the cells in 37°C/5% CO2 incubator until analysis. Cells would become 
adherent one to three days after PMA treatment. 
 
NLRP3 inflammasome activation  
In 293-ASC-caspase-1-IL1 cells system, NLRP3 inflammasome was activated 
by over-expression of adaptor protein NLRP3, which would lead to oligomerization of 
ASC, activate caspase-1 and cleave pro-IL-1. Cell lysates and cell supernatants were 
collected to determine the caspase-1 activity and the IL-1 release level in the 
supernatant.  THP-1 cells are treated with PMA (10 ng/mL) overnight for differentiation 
in 6 well-plate at 2M cells per well. THP-1 cells must be subculture before the density 
reaches 1M/ml. The cells are sub cultured to a density between 0.3-0.5 M/ml. The 
medium need to be changed every 2 to 3 days. On the stimulation day, THP-1 
macrophages are first primed with LPS (100 ng/mL) for 3 h. After priming, the cells 
were washed with PBS for two times to remove the residue of LPS. For stimulation, 
dilute different ligands using serum free medium (OPTI-MEM) to stimulate the cells for 
different time points as the experiment designed. Silica (500 ug/ml), MSU (500 ug/mL), 
CPPD (500 ug/mL) were used to stimulate NLRP3 inflammasome by 6 h stimulation. 
ATP (5mM), Nigericin (5 uM) were used for NLRP3 inflammasome activation by 1 h 
treatment. 
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Results 
 
Screening of DDX family proteins for NLRP3 inflammasome activation 
NLRP3 inflammasome can be activated by various categories of inducers. These 
ligands vary from pathogenic compartments to sterile stimulations. We hypothesized that 
NLRP3 acts as an adaptor of the signaling by sensing the upstream signals from specific 
sensor of different ligands, and interacting with ASC to form inflammasome.  DDX 
family proteins contain RNA helicase domain, thus we suspect that DDX family proteins 
might play a role in NLRP3 inflammasome activation utilizing their DNA/RNA binding 
domain to sense, for example, DNA or RNA ligands from either dying cells or 
pathogens. We purchased the cDNA library for gateway cloning system, and constructed 
cDNA of DDX family genes into tagged pcDNA3.1 vector. After maxi-prep and 
purification of the plasmids, we transfected the plasmids into 293T cells so that the 
protein expression and the correct size of the expressed protein were validated. The next 
step is to test the role of DDX proteins in inflammasome activation. Here, we utilized a 
293T engineered cell line which stably over-expresses ASC, pro-caspase-1 and pro-IL-
1reconstituting the inflammasome activation moduole. These genes were transduced 
into the cells using lenti-virus that packaging the expressing DNA fragment of the 
indicated genes.  For the screening, we co-transfected NLRP3 plasmid with different 
DDX expressing plasmids into the 293 engineered cells. The medium were changed 24 h 
after transfection. And the cell supernatants were collected 48 hours after transfection.  
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Figure 19. Screening of DDX family in cellular reconstituted inflammasome system. 
(A) 293-ASC-caspse-1-IL-1 cells were transfected with NLRP3 with or without HA 
empty vector, HA-tagged DDX4, DDX11, DHX16, DDX19B, DDX21, DDX39A and 
DDX46. Cell supernatants at 48 h after transfection were collected to measure IL-1 
release by ELISA. (B) 293-ASC-caspase-1-IL-1 cells were transfected with control 
vector or HA-DDX46, and co-transfected with NLRP3, AIM2, NLRC4 or NLRP1. Cell 
supernatants at 48 h after transfection were tested for IL-1 release using ELISA. 
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We found that among these DDX proteins, DDX46 enhanced caspase-1 activation and 
IL-1 release detected by ELISA (Figure 19). 
 
Over-expression of DDX46 in 293T cells activates NLRP3 inflammasome 
NLRP3 inflammasome is known to be activated by multiple sources of ligands, 
which vary from pathogen derived molecules such as viral RNA, viral DNA and 
bacterial toxins, to sterile inducers such as ATP, Alum, and silica. We addressed the 
question that how the innate immune system senses different type of inducers, and 
transmits these activating signals down to the inflammasome effectors, which activate 
the caspase-1 and lead to the cleavage of pro-IL-1 and pro-IL-18. Researchers have 
found several DNA sensors able to detect DNA and activate NF-B or inflammasome 
pathway(Brodsky, 2013; Parvatiyar et al., 2012; Zhang et al., 2011).  From our 
preliminary screening, we found that DDX46 may play an important role in promoting 
NLRP3 inflammasome activity in 293T engineered cell system. To validate the function 
of DDX46, we first transfected 293-ASC-caspase-1-IL-1 cells with different amount of 
DDX46 expressing plasmid. We found that DDX46 overexpression alone did not 
activate pro-caspase-1 cleavage. We co-transfected NLRP3 with empty vector or dose 
gradient of DDX46, and we found that NLRP3 over-expression enhanced the caspase-1 
activation. More importantly, we observed that co-transfection of DDX46 and NLPR3, 
further enhanced caspase-1 activation to an extent significantly higher than that with 
NLRP3 alone. And this enhancement is dependent on the dose of DDX46 transfection  
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Figure 20. Exogenous expression of DDX46 enhances NLRP3 inflammasome. (A) 
293-ASC-caspase-1-IL-1 cells were transfected with or without HA-NLRP3 plasmid 
together with dose gradient of Flag-DDX46 plasmid. Cell lysates were collected using 
low salt lysis buffer, and the activation of caspase-1 were tested by western blot to check 
the blot of cleaved caspase-1, P20. (B) Cell supernatant from the transfected cells in (A) 
were collected, and the release of human IL-1 were measured by ELISA. 
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(Figure 20). Using the same system, we measured IL-1 release in the cell supernatants 
and found that co-transfection of DDX46 and NLRP3 increased the IL-1 release in 
response of NLRP3 inflammasome activation, further supported the statement that 
exogenous expression of DDX46 in 293-ASC-capsase-1-IL-1 cells enhances NLRP3 
inflammasome. 
 
Knockdown of endogenous DDX46 in 293T-ASC-capase-1-IL-1 cells decreased 
NLRP3 inflammasome activity 
Now that overexpression of DDX46 increased caspase-1 activation in 293T-
ASC-caspase-1-IL-1 cells transfected with NLRP3. However, exogenous over-
expression of proteins may modify the original function of a protein. Thus, a method to 
decrease or abort the expression of endogenous expression of the gene is needed to 
verify the statement. We picked up DDX46 shRNA from the shRNA library purchased 
from Addgene. shRNA knockdown efficiency was first tested in 293T cells by 
transfecting the DDX46 expressing plasmid and DDX46 shRNA and detecting DDX46 
protein expression by western blot. We picked the shRNA with the highest efficiency for 
DDX46 knowckdown in 293T cells. Using this shRNA, we knocked down DDX46 in 
293T-ASC-caspse-1-IL-1 cells, and transfected the cells with NLRP3, cell lysates 48 
hour after transfection were analyzed for caspase-1 activation. When the cells were 
transfected with DDX46 shRNA, the activated caspase-1 reduced significantly 
comparing to the cells transfected with control shRNA (Figure 21A). When we looked  
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Figure 21. DDX46 knockdown reduced the NLRP3 inflammasome in 293-ASC-
caspase-1-IL-1 cells. (A) 293-ASC-caspase-1-IL1 cells were transduced with 
lentivirus to stably express NLRP3. The generated stable cells were co-transfected with 
dose-gradient Flag-DDX46 and control shRNA or DDX46 shRNA. Cell lysates at 48 h 
after co-transfection were collected and the activated caspase-1 was tested by western 
blot. (B) Cell supernatants of the transfected cells in (A) were collected, and the cytokine 
level of IL-1 was tested using ELISA. 
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into the IL-1 release in the supernatant, we also observed a decreased secretion level of 
mature IL-1 when the DDX46 was knocked down using DDX46 shRNA (Figure 21B). 
 
Knockdown of DDX46 in THP-1 cells reduce inflammasome activity after 
crystalline stimulations 
THP-1, derived from a patient with acute monocytic leukemia, is a human 
monocytic cell line. It is widely used as a model system for innate immune responses in 
human immune cells. THP1 cells are usually differentiated into THP-1 macrophages 
using PMA (50 nM). However, we concerned that high dose of PMA may affect the 
immune response of THP-1 macrophages or the cells may already be activated when 
treated with high dose of PMA. We looked up the literature, and found that one group 
tested the immune response of THP-1 macrophages after differentiation using different 
dose of PMA, and they found that 10 nM of PMA is effective for differentiation into 
human macrophages and low enough to avoid impact on immune responses(Park et al., 
2007). We also tested the condition, and found that the 5 nM is the good concentration 
of THP-1 differentiation. 
Different dose of DDX46 siRNA was tested to reach the highest knockdown 
efficiency in THP-1 cells. Aiming to maintain the highest viability of transfected THP-1 
cells, I used electroporation protocol with a high survival rate, while use higher dose of 
siRNA to improve the efficiency. DDX46 knockdown were validated by Real-time PCR 
using the total mRNA, and the knockdown efficiency was shown to be as high as 80% 
for DDX46 (Figure 22A). THP-1 cells were first transfected with control or DDX46  
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Figure 22. Knockdown of DDX46 reduced crystal induced IL-1 release in THP-1 
cells.  (A) THP-1 cells were transfected with scramble siRNA or DDX46 siRNA using 
nucleofector kit V by electroporation. Cells were incubated in culture medium with 
PMA (10ng/ml) for 20 h after electroporation. Total RNA were collected for Real-time 
PCR. (B) THP-1 cells were transfected with scramble siRNA or DDX46 siRNA as 
mentioned in (A), after recovery and differentiation in the culture medium with PMA for 
20 h, the cells were first primed with LPS (100 ng/ml), and then after wash with PBS, 
the cells were treated with multiple inflammasome inducers as indicated for 6 h, or 1h 
for ATP and nigerine. Cells supernatant were collected to measure the IL-1 release 
after stimulations. 
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siRNA by electroporation, and then seeded with PMA (5 nM) overnight for 
differentiation.  On the second day, the differentiate cells were first primed with LPS for 
3 hours to initiate the transcription of NLRP3 and pro-IL-1. Then, I washed the cells 
for twice with PBS to remove the residue of LPS to avoid the effects of LPS upon 
inflammasome activation if there would be. Cells were treated with NLRP3 
inflammasome inducers for indicated hours. I tested the mature IL-1 release in the cell 
supernatant, and I found that DDX46 knockdown using DDX46 siRNA significantly 
reduced the IL-1 release in response of crystalline stimulations, such as alum, silica 
CPPD (Figure 22B). However, the IL-1 release in response to other categories of 
stimulations did not vary between knockdown and control groups, indicating that 
DDX46 promotes NLRP3 inflammasome specifically in response of crystalline 
stimulations. This result showed a potential importance of the discovery of the function 
of DDX46 in inflammasome activation, because crystalline stimulation, for example, 
alum, has been widely used as adjuvant to enhance the adaptive immunity or T cell 
activation. In other words, the mechanism how DDX46 senses the crystalline ligands 
and leads the signals to NLRP3 and ASC may explain the mystery of adjuvant 
immunity. 
 
DDX46 is ubiquitously expressed and is not induced by multiple stimulations 
Considering DDX46 overexpression enhanced NLRP3 inflammasome activity, 
we hypothesized that DDX46 is specifically expressed in immune cells or tissues, and is 
induced by pathogen-associated molecule patterns, damage associated molecule patterns 
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or immune responsive cytokines. We purchased the mRNA samples of different mouse 
tissues from open-biosystem, and generated the complementary cDNA by reverse 
transcription. DDX46 mRNA expression was tested by quantitive Real-time PCR. 
DDX46 is actually ubiquitously expressed in different tissue, such as lung, heart, spleen, 
testis, brain and other tissues (Figure 23A). To test if the gene expression of DDX46 is 
induced by stimulations, peritoneal macrophages were collected from B6 WT mice. The 
cells were treated with LPS, IFN- and IFN-. DDX46 was found not to be induced by 
any of the stimulation added (Figure 23B). These results indicated that the regulation of 
NLRP3 inflammasome by DDX46 is not dependent on the regulation of DDX46 
expression. Other Mechanisms, for instance, post-transcriptional modification of the 
protein or conformational change of the molecule leading to functional activity change 
may contribute to the function of DDX46 in inflammasome activation. What we need to 
do is to examine the protein of DDX46 to check if the protein is modified or processed 
after translation before or after ligands stimulation in our THP-1 cells system. 
 
DDX46 is cleaved after crystalline stimulation in THP-1 cells 
As DDX46 transcription level is not affected by LPS stimulation, we 
hypothesized that DDX46 is modified after the cells are treated with the crystalline 
stimulations, changing the activity of DDX46 to activate NLRP3 inflammasome. To test 
this hypothesis, primed THP-1 cells were treated with multiple NLPR3 inflammasome 
inducing stimulations, such as poly (I:C), ATP, MSU, CPPD, silica and alum. Cell  
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Figure 23. DDX46 is ubiquitously expressed and is not induced by LPS, IFN-, or 
IFN-. (A) Total RNA of different tissues of human being was purchased from open 
biosystem, and the complementary cDNA were generated using reverse transcriptase. 
DDX46 expression pattern in different human tissues were determined by Real-time 
PCR using the cDNA. (B) WT peritoneal macrophages were obtained from B6 mice. 
The cells were treated with LPS (100 ng/ml), IFN- (10 ng/ml), and IFN- (10 ng/ml) 
for different time points. Total RNA was collected using TRIzol, and the DDX46 mRNA 
expression were determined by Real-time PCR. 
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lysates of the cells after stimulation were collected and analyzed for DDX46 protein by 
western blot. Strikingly, I found that even though DDX46 was ubiquitously expressed 
after different stimulations, the protein is processed or cleaved into smaller size of  
protein when the cells were specifically treated with crystalline ligands such as alum and 
silica (Figure 24). This discovery gave us a light on the mechanism of how DDX46 
affect the activation of NLPR3 inflammasome in response of crystalline stimulations. 
This cleaved form of DDX46 might be important to transduce the danger signal to 
downstream molecules. There are several possibilities that could explain the function of 
DDX46. One is that DDX46 can interact with NLRP3 when it is activated. Another 
possibility is that activated form of DDX46 can bridge the interaction of NLRP3 and 
ASC to form the platform. Or DDX46 affects the activity of cathepsins which play 
important role for NLRP3 inflammasome activation after crystalline stimulations. To test 
these possibilities, we would like to move the system back to 293T cells for molecule 
mechanisms. 
 
Interaction between NLRP3 and DDX46 in 293T cells 
NLRP3 was first found to be important for inflammasome activation by 
Tschoop’s report stating that NLRP3 interacts with ASC and forms a complex or 
platform which leads to pyroptosis(Agostini et al., 2004). We found that DDX46 
affected NLRP3 inflammasome activation in response of silica and alum. Thus, we 
hypothesized that DDX46 may interact with important components or signaling 
molecules in inflammasome signaling pathway.  Firstly, it would be necessary to check  
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Figure 24. DDX46 is cleaved after silica and alum stimulation. THP-1 cells were 
primed with LPS for 3 hours, and then washed with PBS for one time. The cells were 
then transfected with Poly(dA:dT) (1 ug/ml), poly(I:C) (1ug/ml), or poly(dG:dC) 
(10ug/ml) uing lipofectamin 2000, or treated with MSU (200 ug/ml), alum (500 ug/ml), 
silica (500 ug/ml), CPPD (200 ug/ml) for 6 h. Other cells were treated with ATP (5 mM) 
or Nigericin (1 nM ) for 1 h. Cell lysates and supernatants were collected for western 
blot.  
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if exogenous expression of DDX46 could interact with NLRP3, ASC or other 
inflammasome compartments. DDX46 and NLRP3 were co-transfected into 293T cells 
to check the interaction between exogenously expressed DDX46 and NLRP3. Also we 
checked the interaction between DDX46 and other proteins such as NLRP1 and AIM2 
by the same method. HA-tagged DDX46 were co-transfected with Flag-tagged NLRP3, 
NLRP1, AIM2 or empty-vector in 293T cells. Cell lysates were used for 
immunoprecipitation using anti-HA beads. Then the pulled down protein lysates were 
analyzed by western blot and blotted by anti-Flag antibody. We found that DDX46 could 
interact with NLRP3 but not other proteins such as NLPR1 and AIM2 (Figure 25A).  
When we over-expressed DDX46 with ASC in 293T cells, we also found interaction 
between ASC and DDX46 (Figure 25B). Accordingly, we hypothesize that DDX46 may 
function as an adaptor to bridge the interaction between NLRP3 and ASC. 
 
DDX46 forms a complex with NLRP3 and ASC in THP1 cells after silica 
stimulation 
As in 293T cells, we found that DDX46 over-expression specifically enhanced 
NLRP3 inflammasome activation, and in THP-1 cells, knockdown of DDX46 leaded to 
decrease of IL-1 release after NLRP3 inflammasome activation in response of silica 
stimulation. We already checked that exogenous DDX46 interacts with NLRP3 and ASC 
in 293T cells, we hypothesized that DDX46 interacts with NLPR3 and ASC in LPS-
primed THP1 cells after silica stimulation. Moreover, we were also interested to see 
when DDX46 starts to interact with NLRP3 or ASC, thus we carried out a time course  
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Figure 25. Exogenous DDX46 interacts with NLRP3 and ASC. (A) HA-tagged DDX 
family proteins were co transfected with Myc-NLRP3 in 293T cells. Cell lysates were 
used for immunoprecipitation to pull down HA-tagged proteins to detect interacted 
NLRP3 by western blot. (B) 293T cells were co-transfected with HA-DDX46 and Myc-
ASC. Cell lysates were used for immunoprecipitation to pull down HA-tagged DDX46 
and to detect Myc-ASC by western blot. 
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treatment of silica in LPS-primed THP-1 cells, to detected the interaction by 
immunoprecipitation.  We fist differentiated the THP-1 cells into attaching THP-1 
differentiated macrophages with PMA, and primed the cells with LPS for 3 hours on the 
stimulation day. Cells were then treated with silica for different time points after cell 
washing with PBS. Cell lysates were collected for immunoprecipitation. 
We found that after THP1 cells were primed by LPS, DDX46 started to interact 
with NLRP3, and this interaction did not significantly increased when the cells were 
treated with silica for 2 or 3 hours. On the other hand, DDX46 does not interact with 
ASC in absent of silica stimulation, but DDX46 starts to interact with ASC at 2 h after 
stimulation and strongly interacts with ASC at 3 h after stimulation, when DDX46 is 
strongly interacted with NLRP3 (Figure 26). Notably, DDX46 was cleaved at 3 h after 
silica stimulation, suggesting that cleaved form of DDX46 has stronger ability to interact 
with ASC, bringing ASC to NLRP3 for inflammasome platform formation. We also 
checked the interaction between NLRP3 and ASC after silica stimulation. We found that 
NLRP3 did not interact with ASC at the early time points, but strongly interacted with 
ASC at  3 hours after stimulation, which supported the hypothesis that DDX46 is 
cleaved after silica stimulation, and cleaved DDX46 bridges the interaction between 
NLRP3 and ASC for inflammasome activation. These results provided bases for our 
working model in which DDX46 bring NLRP3 to ASC for pyroptosis platform 
formation in response of silica stimulation.  
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Figure 26. Cleaved DDX46 forms a complex with NLRP3 and ASC. THP-1 cells 
were primed with LPS for 3 h, and then the cells were treated with silica ( 500 ug/ml) for 
indicated time points after wash with PBS. Cell lysates were collected for 
immunoprecipitation and the interaction between ASC or NLRP3 with DDX46 were 
detected by western blot.  
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DDX46 promotes the interaction between NLRP3 and ASC after silica stimulation 
in THP-1 cells 
Regarding the fact that DDX46 interacts with the complex involving NLRP3 and 
ASC at least 3 hours after stimulation, we hypothesized that DDX46 bridges the 
interaction between NLRP3 and ASC after silica stimulation. To verify this hypothesis, 
it is important to remove the function of DDX46 and check the immune-response of the 
cells without DDX46 or with low level of DDX46 protein. The method we used is to 
knockdown the DDX46 in THP-1 cells by transfecting the cells with siRNA targeting 
DDX46 with low off-target. We transfected the THP-1 cells with DDX46 siRNA using 
electroporation, and checked the expression of inflammasome related protein expression. 
DDX46 was efficiently reduced by siRNA transfection. And the expression level of pro-
caspase-1, ASC and NLRP3 were comparable between the group transfected with 
DDX46 siRNA and that with control siRNA (Figure 27A). The transfected cells were 
differentiated into macrophages and primed with LPS to initiate the NLRP3 and pro-IL-
1 expression. Then, the cells were treated with silica for 3 hour, a time point we know 
that NLRP3 strongly interact with ASC. We carried out immunoprecipitation using the 
cell lysates to check the interaction between ASC and NLRP3 after stimulation in these 
two groups that were transfected with DDX46 siRNA and control siRNA respectively. 
The western blot showed that the interaction between NLRP3 and ASC was markedly 
reduced when DDX46 was knockdown in the THP-1 cells (Figure 27B), while the 
expression of ASC and NLRP3 are similar between these two groups. In sum, DDX46  
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Figure 27. DDX46 knockdown reduced the interaction between NLRP3 and ASC 
after silica stimulation. (A) THP-1 cells were transfected with control siRNA or 
DDX46 siRNA by electroporation. Cell lysates were collected for western blot. (B,C) 
THP-1 cells were transfected with control siRNA or DDX46 siRNA, and cultured in 
PMA containing medium for 20 h. Cells were then primed with LPS and treated with 
silica for 3 h (B) or indicated hours (C). Cell lysates were collected after stimulation and 
used for immunoprecipitation. 
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plays an important role in resulting in the interaction between NLRP3 and ASC in 
response of silica stimulation. It can explain why knockdown of DDX46 reduced the IL-
1 release in response of crystalline stimulations in THP-1 cells. We also did a time 
course to detect the interaction between NLRP3 and ASC after silica stimulation in cells 
transfected with DDX46 siRNA. Consistently, we found that knockdown of DDX46 by 
siRNA reduced the interaction between NLRP3 and ASC at 3 h and 4 h after silica 
stimulation (Figure 27C). In addition, the active caspase-1 in the supernatant also 
decreased in the DDX46 knockdown cells. 
 
DDX46 C-terminal deletion has stronger ability to stimulate NLRP3 inflammasome 
in 293T-ASC-caspase-1-IL-1 cells 
As we found that DDX46 was cleaved at 3 hour after silica stimulation in THP-1 
cells, co-existing with the occurrence of the interaction between NLRP3 and ASC, and 
the cleaved DDX46 also interacted with NLRP3 and ASC at 3 hour after silica 
stimulation. We suspected that cleaved DDX46 has physiological function to activate 
NLRP3 inflammasome. Here we go back to 293T engineered cell system to work on the 
molecule mechanism of the function of DDX46. I designed primers and amplified the 
cDNA that only express amino acids from the first one to the 992 th amino acid, a 
fragment that only express the truncation of the DDX46 protein lacking the C-terminus, 
and I referred this protein as DDX46 C. Utilizing the 293T engineered system, I 
transfected the cells with NLRP3 and then co-transfected with DDX46 FL plasmid or  
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Figure 28. DDX46 C has stronger ability to promote NLRP3 inflammasome. (A) 
293-ASC-caspase-1-IL-1 cells were co-transfected with NLRP3 and DDX46 or 
DDX46 DC of different doses. Cells lysates collected 24 h after transfection were 
analyzed for caspase-1 activation by western blot. (B) Cell supernatants of the 
transfected cells in (A) were analyzed for IL-1 release by ELISA. 
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DDX46 C plasmid. When I examined the caspase-1 cleavage of the cells using the cell 
lysates, I found that even though DDX46 full length itself enhanced the NLRP3 
inflammasome activity by increasing the pro-caspase-1 cleavage, DDX46 C further 
enhanced the inflammasome activity to higher extent by showing significantly stronger 
signal of P20 of caspase-1 (Figure 28A). Similarly, we measured the secretion of human 
IL-1and consistently we found that DDX46 C co-transfection led to a significantly 
higher level of IL-1 release compared to that transfected with DDX46 full length gene 
(Figure 28B). This result indicated that the cleaved form of DDX46 after silica 
stimulation has got a physiological function to enhance the NLRP3 inflammasome, but 
the full length form of DDX46 does not have the activity to stimulate NLRP3 
inflammasome.  
 
Exogenous DDX46 C interacts with NLRP3 and strongly with ASC  
In the THP-1 cells we found that cleaved DDX46 can interact with the complex 
formed by NLRP3 and ASC 3 hours after silica stimulation. Thus, it would be 
interesting to check if exogenous DDX46 C has the activity to interact with NLRP3 or 
ASC. I transfected 293T cells with Flag-tagged DDX46 or DDX46 C and HA-tagged 
NLRP3, cell lysates were collected 24 hours after transfection to test the interaction 
between overexpressed DDX46 and NLRP3. By incubating the lysates with anti-HA 
beads, the overexpressed NLRP3 and its potential interacting molecules in the cell lysate 
bound to the beads, and was later precipitated through centrifugation with  
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Figure 29. DDX46 C interacts with ASC and NLRP3. (A) 293 T cells were 
transfected with plasmid of DDX46 and DDX46 C along with NLRP3. Cells lysate at 
24 h after transfection were analyzed by immunoprecipitation an dwestern blot to detect 
the interaction between NLRP3 and DDX46 or DDX46 C. (B) 293T cells were 
transfected with DDX46 or DDX46 C with ASC. The interaction between ASC and 
DDX46 or DDX46 C was determined by immunoprecipitation and western blot. 
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several wash. Finally the interacted proteins were dissolved into the SDS-loading buffer, 
which would be ready for western blot after 5 minutes incubation in 100 degree. 
According to the immunoprecipitation result, the cleaved DDX46 lacking c-terminus and 
the full length DDX46 can both interact with overexpressed NLRP3 (Figure 29A). Using 
the same method, I also checked the interaction between DDX46 C with Myc-tagged 
ASC, and observed that DDX46 C had much stronger ability to interact with 
exogenous ASC than the full length of DDX46 (Figure 29B). These results were 
consistent with those I did in THP1 cells, so that we could conclude that DDX46 can 
constitutively interact with NLRP3 in the cytoplasm, and when itself is cleaved by other 
proteins as the cells are treated with stimulations such as silica, alum, the activated form 
of DDX46 could bring ASC to NLRP3 utilizing its strong affinity to interact with ASC, 
forming a platform formed by oligomerization of NLRP3, ASC and cleaved DDX46. 
This complex after stimulation finally leads to activation of  caspase-1 cleavage. 
 
Caspase-3 cleaves DDX46 after silica stimulation 
As the database estimated that DDX46 can be processed by caspases, we are 
interested to find which caspase is responsible for the cleavage of DDX46 after 
crystalline stimulation in macrophages. Firstly, we screened several caspases such as 
caspase3, caspase 4, caspase8 in THP1 cells using siRNAs targeting these caspases to 
see if the knockdown of specific caspase would have any effect on the cleavage of 
DDX46 after stimulation. In THP1 cells transfected with the control siRNA, caspase4 
siRNA or caspase8 siRNA, DDX46 was cleaved when the cells were treated with silica 
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for 3 hours, however, in those that transfected with caspase-3 siRNA, DDX46 failed to 
be cleaved after stimulation. This result indicated that caspase3 may be the effecter to 
cleave DDX46. For further verification, we move the system to mouse bone marrow 
derived macrophages. After that, the caspases activity was determined in the BMDMs 
after silica stimulation. Using the cell lysates of the cells treated with silica for different 
time points, we found that caspase-3 cleavege was activated 2 hours after silica 
stimulation, and the activity maintained at 3 and 4 hour after stimulation (Figure 30A). 
However, caspase-1 activity or cleavage was not detected until the cells were treated for 
4 hours. Considering DDX46 is cleaved 3 hour after stimulation, we highly suspected 
that caspase-3 play the major role to cleave the DDX46. To further test our hypothesis, 
we ordered B6, caspase-1 knockout, and caspase-3 knockout mice from Jackson’ lab. 
We extracted bone marrow progenitor cells from these mice and have them 
differentiated into bone marrow derived macrophages. We primed the cells with LPS 
and treated the cells with silica for different time points.  The western blot result showed 
that DDX46 is cleaved at 4 hour after silica stimulation in both B6 and caspase-1 
knockout mice cells, however, caspase-3 knockout cells showed a resistance to DDX46 
cleavage. In caspase-3 KO cells the cleavage of DDX46 was abrogated (Figure 30B). It 
gave strong evidence that DDX46 cleavage relies on the activated caspase-3 after the 
cells are treated with silica. Besides, caspase-3 deficiency also led to reduce IL-1 
secretion at 4 h after silica stimulation (Figure 30C). This finding first links caspase-3 to 
pyroptosis, a programmed cell death functions through caspase-1 activation, other than  
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Figure 30. Caspase-3 is essential for DDX46 cleavage after silica stimulation.  
WT BMDMs were primed with LPS, and then treated with silica for indicated time 
points. Cell lysates were analyzed by western blot to exam the activation of caspase-1, 
caspase-3 and DDX46. 
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Figure 30. Continued. 
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apoptosis, providing a new inspect of this protein in the mechanism of programmed cell 
death, and other potential functions.  
 
Working model of DDX46 leaded NLRP3 inflammasome activation 
Based on these results, I generated a cartoon that explains how DDX46 promotes 
NLRP3 inflammasome under crystalline stimulation (Figure 31). In the NLRP3 
expressing cells, DDX46 consistently interacts with NLRP3. When the cells are 
challenged by crystalline stimulations such as silica, alum, caspase-3 is cleaved and 
activated, and the activated caspase-3 processes DDX46, leaving the cleaved form of 
DDX46 interacting with NLRP3. Then, the cleaved DDX46, with its strong ability to 
interact with ASC, brings the NLRP3 to interact with ASC forming a large complex by 
oligomerization of these proteins. And the large protein complex, that we called 
inflammasome, activates caspase-1 cleavage and thus processes pro-IL-1 and pro-IL-
18. The cells are finally led to pyroptosis. 
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Figure 31. Working model of DDX46 in NLRP3 inflammasome. DDX46 interacts 
with NLRP3 in the cytoplasm. When the cells are treated with crystals, caspase-3 is 
activated, and it cleaved DDX46 into a activated form, which could bring ASC to 
NLRP3 and form a large complex of inflammasome. NLRP3 inflammasome cleaves the 
pro-caspase-1 and release the activated caspase-1. 
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Discussion 
 
DDX46 in inflammasome activation 
In this study, by screening of DDX and DHX family members, we have 
identified DDX46 as a critical component of NLRP3 inflammasome activation. This 
inflammasome is critical for caspase-1. DDX46 binds to both NLRP3 and ASC, and 
interestingly, DDX46-ASC binding is dramatically enhanced after crystalline ligand 
stimulation such as silica but not soluble activators such as DNA/RNA ligands or ATP. 
The molecular mechanism of increased binding may involve a possible caspase-3 
dependent cleavage of DDX46 at the C-terminus, eliciting a possible conformation 
change of the DDX46 molecule and facilitating its binding with ASC. Since DDX46 can 
bind to NLRP3, the outcome of increased ASC binding upon stimulation resulted in a 
recruitment of NLRP3 and ASC molecules by DDX46. By bioinformatics prediction, 
DDX46 has two caspase cleavage sites at the C-terminus, they are 871 site, ESQD-
VMQQ and 922 site, ERQD-GGQN. The exact cleavage site needs to be further 
determined by proteomics analysis. By constructing the C truncation of DDX46, we 
indeed found that the ability of truncated DDX46 to activate NLRP3 inflammasome is 
significantly enhanced. The potential molecular mechanism of DDX46 is bridging the 
interaction between NLRP3 and ASC by the truncated form because the DDX46 C 
strongly interacts with ASC whereas the full length does not. Finally, by using caspase-3 
KO mice, we found that caspase-3 activation is needed for crystalline induced DDX46 
processing. It is reported that crystalline stimulation such as silica stimulation will cause 
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apoptosis and necrosis of cells (Joshi and Knecht, 2013). Such necrosis can serve as a 
trigger for inflammasome activation (Li et al., 2009). The cleavage of DDX46 in this 
case acts as a sensor of the necrosis danger signals and activates the NLRP3 
inflammasome. Indeed, caspase-3 knockout BMDMs produced much less IL-1 upon 
silica stimulation in vitro suggesting that the danger signals induced DDX46 cleavage is 
very important in inflammasome activation and may be potentially critical immune 
responses in vivo. The physiological role of DDX46 in inflammasome activation in vivo 
and its sequential importance for adequate immune responses upon crystalline 
stimulation in vivo such as in rheumatoid arthritis remain to be determined by 
constructing a genetic KO model. 
Recently, some of the DDX family members have been identified to play 
important role in type I interferon pathway by directly sensing the ligands or by 
recognizing the secondary messengers. For instance, DDX41 is a sensor for intracellular 
DNA and activates type I IFN signaling through STING in the system built up with 
dendritic cells (Zhang et al., 2011) . DDX41 was also shown to recognize the bacterial 
secondary messengers cyclic di-GMP and cyclic di-AMP to activate type I interferon 
immune response (Parvatiyar et al., 2012). We focused on what DDX or DHX family 
members may function to promote NLRP3 inflammasome activation by sensing the 
stimuli or downstream signals (like secondary messengers). Among the members 
screened in vitro by 293-CIA cells, we identified a positive regulator of inflammasome 
activation, DDX46. It was recently reported that a DExD/H-box helicase superfamily 
member DHX33, a RNA sensor uses NLRP3 to activate the secretion of 
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proinflammatory cytokines. These data strongly suggested that the DExD/H-box 
helicase superfamily is highly utilized by the innate immune system for sensing viral 
infection, bacterial infection as well as danger signals such as crystalline stimulation to 
activate the inflammasome pathways.  
It has been shown that the NLR family members including NOD1, NOD2, 
NLRC4, NLRP1 and NLRP3 are playing critical roles in linking signals from PAMPs 
and DAMPs to the activation of cytosolic inflammatory responses. Our study shows one 
important molecular mechanism of how the assembly of NLRP3 inflammasome 
platform with ASC is formed. Recent studies showed that DHX33 or NAIP senses 
specific ligands and interacts with their adaptors NLRP3 and NLRC4 respectively to 
trigger inflammasome activation(Brodsky, 2013; Mitoma et al., 2013). It is still not clear 
what could be the sensors of crystalline stimulators such as silica and alum, which are 
proved to be very critical causes of lung inflammation and adjuvant respectively. Some 
crystalline stimulus such as uric acid crystals can cause gout by inflammasome 
activation at the joints. It is found that these crystallines have common features of 
causing the release of ‘danger signals’ from dying cells. Cell death is usually mediated 
by some death associated caspases, caspase 3, 6, 7. We found that the death pathway 
which activates caspase-3 may be a bridge between the danger signal and the activation 
of inflammasome. Because the activation of caspase-3 can mediate the cleavage of 
DDX46, rendering a much potent form of the molecule to bridge the interaction between 
NLRP3 and ASC, two pivotal components of inflammasome platform. Although not a 
single sensor of crystalline has been successfully identified to activate NLRP3 
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inflammasome so far, our data provide a molecular basis of how the cell “senses” danger 
signals from dying cells caused by engulfing the insoluable crystals. Thus, our study 
may shed new light on crystalline induced pathology and these findings may provide 
important clues for development of specific and effective therapies for inflammatory 
diseases such as gout and pneumonoultramicroscopicsilicovolcanokoniosis.  
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CHAPTER IV 
CONCLUSION 
 
In the first part, NLRC5 deficient mice were characterized to verify the function 
to regulate NF-B signaling, type I IFN signaling and MHC I expression. We observed 
that NLRC5 ablation in MEFs and macrophages resulted in promoted NF-B signaling 
and pro-inflammatory cytokine secretion level after the cells are treated with TLR 
ligands. In addition, NLRC5 deficiency increased type I IFN signaling activity as well as 
anti-rival responses in mouse-differentiated MEFs and mouse macrophages when the 
cells were challenged with virus or TLR3 agonists. Also, significantly reduced MHC I 
expression was observed in NLRC5
-/-
 T cells. In summary, NLRC5 negatively regulates 
TLR ligand-induced NF-B signaling and type I IFN signaling pathway under 
physiological conditions in mouse MEFS and macrophages. NLRC5 also positively 
regulates the expression and presentation of antigen presenting molecule, MHC class I, 
in lymphocytes. 
In the second part, by knocking down DDX46 in THP-1 cells, we found that 
reduced expression of DDX46 led to decreased interaction between ASC and NLRP3, as 
well as reduced secretion of mature IL-1 after treatment of crystals such as silica and 
alum. This result confirmed our finding in 293-ASC-caspase-1-IL-1 cells that DDX46 
overexpression enhanced the NLRP3 inflamamsome. Furthermore, DDX46 is cleaved by 
caspase-3 in response of silica stimulation, and the cleaved DDX46 strongly interacts 
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with ASC, and brings ASC to NLRP3, which DDX46 constantly interacts with. Thus, 
cleaved DDX46 enhanced silica induced NLRP3 inflammasome activation. 
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